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INTRODUCTION 
The fundamental principle of pharmacology is that a relationship exists between 
the concentration of a drug at its site of action and its beneficial or toxic action.1 The 
availability of a drug substance to the biologic system formulated into a pharmaceutical 
product, is integral to the goals of dosage form design and paramount to the effectiveness 
of the medication.2 In the majority of cases, substances are intended to exhibit a systemic 
therapeutic effect in the general circulation in exchange with the substance at the site of 
action.3 
 Variations from one individual to another in absorption, metabolic conservation 
and excretion of the drug along with its excipients and simultaneous use of other drugs 
can affect or alter the action of the prescribed drug. Such factors may greatly influence 
the therapeutic effect obtained from drug products. The therapeutic effect of a drug 
product is assumed to be a function of the concentration of the active ingredient in the 
systemic circulation and thus related to its bioavailability.4 
The concept of bioavailability and bioequivalence plays an important role in drug 
research and development, especially in generic-drug industry. Generic drug makers do 
not develop a drug from initial stage. Therefore generic drugs are less expensive than 
branded drugs. The studies of bioavailability and bioequivalence provide an objective 
means of critically assessing the possibility of alternate use of drugs in different 
formulations. When a major formulation change occurs or a generic equivalent of an 
originator formulation desire market approval, a clinical comparative study is the most 
obvious to show bioequivalence.5 
 This circumstantial growth of generic pharmaceutical industry and the abundance 
of multisource products have prompted some questions among healthy professionals and 
scientists regarding the therapeutic equivalency of these products. Inherent in the 
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currently accepted guidelines for product substitution is the assumption that a generic 
drug considered to be equivalent to a brand name drug would elicit the same clinical 
effect.4 
            However for most nominally equivalent pharmaceutical products(including solid 
oral dosage forms), a demonstration of therapeutic equivalence can and should be carried 
out, and such assessment should be included in the documentation for marketing 
authorization. 
           This Bioavailability and Bioequivalence   refers to the marketing of 
pharmaceutical products that are intended to be therapeutically equivalent, and thus 
interchangeable, but produced by different manufacturers 
 
Bioavailability 
              Bioavailability is the term used to indicate the fractional extent to which a dose 
of drug reaches its site of action or a biological fluid from which the drug has access to its 
site of action.7 
               Bioavailability is defined as the rate and extent of absorption of drug from a 
dosage form as determined by its concentration – time curve in blood or excretion in 
urine. It is a measure of fraction of administered dose that reaches systemic circulation in 
unchanged form.6,  
Bioequivalence 
  Two pharmaceutically equivalent drug are considered to be bioequivalent when 
the rate and extent of the active ingredient in the two products are not significantly 
different under suitable test conditions. 8 
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Oral formulations of a drug from different manufacturer or different batches from 
same manufacturer may have the same amount of drug but may not yield same blood 
levels and are biologically inequivalent.8 
            Basically bioequivalence testing is performed to see, if the products are 
pharmaceutically in equivalentand pharmacokinetics in terms of exposure time profile so 
as to ensure same therapeutic outcome. 
Tenofovir 
Tenofovir belongs to class of antiretroviral drugs known as nucleotide analogue 
reverse transcriptase inhibitors (NtRTIs), which block reverse transcriptase, an enzyme 
crucial to viral production in HIV-infected people. Now it has been developed active 
against Hepatitis B virus DNA polymerase in Hepatitis B infected people.9 
Tenofovirdipivoxilfumarate (9-[(R)-2-[[bis(pivaloyloxymethoxy)phoshinoyl ] methoxy 
propyl] is a novel ester prodrug of tenofovir. 
Tenofovirdisoproxilfumarate  is an acyclic nucleoside phosphonatediesteranalog 
of adenosine monophosphate, Tenofovir requires initial diester hydrolysis for conversion 
to Tenofovir and subsequent phosphorylations by cellular enzymes to form 
tenofovirdiphosphate,This form not only improves bioavailability and increases  
intracellular passage of active form. 10 
 The purpose of this  study was  to compare the pharmacokinetic parameters  of  
Tenofovir  245 mg (test) tablet of  one company with that of the reference product 
Tenofovir 245 mg (viread®) tablet. In addition, the bioavailability and bioequivalence was 
evaluated in healthy male human volunteers under fed conditions in a single 
comparatively equivalent dose. 
Review Of Literature 
 
INSTITUTE OF PHARMACOLOGY, MMC Page 4 
 
REVIEW OF LITERATURE 
Pharmacokinetic concepts are used during drug development to determine the 
optimal formulation of a drug, dose (along with effect data), and dosing frequency.  A 
drug’s pharmacokinetic profile has important clinical significance beyond its use in drug 
development.  Even the most promising pharmacologic therapies will fail in clinical trials 
if the drug is unable to reach its target organ at a concentration (fraction) sufficient to 
have a therapeutic effect.11 
Bioavailability (designated as F) is defined as the fraction of administered drug 
reaching the systemic circulation as intact drug.12 Bioavailability is highly dependent on 
both the route of administration and the drug formulation.11 
Different routes of administration vary or reduce bioavailability as in case of 
drugs administered as subcutaneous, oral, rectal and other extravascular routes as in these 
routes the drugs should be absorbed whereas, when given as intravenous formulation the 
bioavailability always remains 100%.13 This property of a dosage form has historically 
been identified as physiologic availability, biologic availability or bioavailability.3 
Bioavailability captures two essential features, namely how fast the drug enters the 
systemic circulation (rate of absorption) and how much of the nominal strength enter the 
body (extent of absorption).3 
Factors influencing bioavailability: 
 Various physiological factors reduce the availability of drugs prior to their entry in 
to the systemic circulation.14 
• Physical properties of the drug 
• Drug formulation 
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• Drug administered with or without food 
• Gastric emptying rate 
• Circadian differences 
• Enzyme induction/inhibition by other drugs/foods. 
• Disease state (poor renal function) 
Each of these factors may vary from individual to individual (inter-individual 
variation), and indeed in the same individual over time (intra-individual variation). 
Types of bioavailability:11, 14 
 Absolute Bioavailability (F): 
When the systemic availability of a drug administered orally is determined 
in comparison to its intravenous administration, it is called as absolute 
bioavailability. 
 Comparative Bioavailability (F): 
When the systemic availability of a drug after oral administration is 
compared with that of an oral standard of the same drug (such as an aqueous or 
non-aqueous solution or a suspension) it is referred as relative or comparative 
bioavailability. 

 Supra Bioavailability:4 
Suprabioavailability is a term used when a test product displays larger 
bioavailability than the reference product.  Such formulations are usually not to be 
accepted as therapeutically equivalent to the existing reference product. 
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
 Measurements of bioavailability: 14 
The methods useful in quantitative evaluation of bioavailability can be 
divided into 2 categories. 
1. Pharmacokinetic methods(indirect method) 
A. Plasma level-time studies. 
B. Urinary excretion studies. 
2. Pharmacodynamic methods(direct method) 
A. Acute pharmacological response. 
B. Therapeutic response. 
Pharmacokinetic Parameters:15 
  The main pharmacokinetic parameters that are used in determining the 
bioavailability of a drug from a drug product is defined by measuring time of peak plasma 
concentration (Tmax), peak plasma concentration (Cmax), area under the plasma 
concentration time curve (AUC). 
               The first two parameters are simple indicators for rate of absorption.  An 
increased rate means a higher peak at a shorter time.  In contrast, the third parameter 
AUC reflects the extent of absorption.  It denotes the total amount of drug absorbed into 
the circulation in a specified period.  For a product to be considered bioequivalent, all the 
three parameters should not be significantly different.  The quantitative evaluation of 
bioavailability of any oral dosage form can be done by comparing the AUC obtained after 
oral administration of a single dose with that obtained when the same drug in the same 
dose is given as intravenous formulation.14 
 INSTITUTE OF PHARMACOLOGY, MMC
 
  
Fig 2.1-Plasma- concentration time profile showing pharmacokinetic parameters 
AUCo-t:    The area under the plasma concentration versus time curve, from time
    zero to the last measurable concentration, as calculated by the linear 
   trapezoidal method.
AUCo-infinity:  The area under the plasma concentration versus time curve, from time
    zero to infinity.  AUCo
    ratio of the last measurable plasma concentration to the elimination 
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rate constant.12, 15 
Cmax:    Maximum concentration measured in the blood. 12, 15 
Tmax:    Time of the maximum measured plasma concentration. If the 
    maximum value occurs at more than one time point, Tmax is defined 
   as the first time point with this value.15 
Kel:    Apparent first-order terminal elimination rate constant calculated from 
   a semi-log plot of the plasma concentration versus time curve. 
T1/2:    The apparent first-order terminal elimination half-life will be 
   calculated as 0.693/Kel. 
Objectives of bioavailability studies:15 
 Primary stages of development of a suitable dosage form for a new drug entity to 
obtain evidence of its therapeutic utility. 
 Determination of influence of excipients, patient related factors and possible 
interaction with other drugs on the efficiency of absorption. 
 Development of new formulation of the existing drugs. 
 Control of quality of a drug product during the early stages of marketing in order 
to determine the influence of processing factors, storage and stability on drug 
absorption. 
 Comparison of availability of a drug substance from different dosage forms or 
from the same dosage form produced by different manufacturers. 
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BIOEQUIVALENCE:16 
 Bioequivalence is defined as the absence of significant difference in the rate and 
extent to which active ingredient or active moiety in pharmaceutical equivalent or 
pharmaceutical alternative become available at the site of drug action when administered 
at the same molar dose under similar conditions in an appropriately designed study. 
Factors influencing bioequivalence:16 
• Delayed gastric emptying. 
• Stimulation of bile flow 
• Change in gastrointestinal (GI) pH. 
• Increase splanchnic blood flow. 
• Change in luminal metabolism of a drug substance. 
• Physical or chemical interaction with a dosage form or a drug substance. 
 Food can change the BA of a drug and hence can influence the BE between test 
and reference products. 
Types of bioequivalence: 
Chemical equivalence:14, 2 
 It indicates that two or more drug products contain the same labelled chemical 
substance as an active ingredient in the same amount. 
Pharmaceutical equivalence: 
 It is a relative term which denotes that the drug substances in two or more forms 
are identical in strength, quality, purity, content uniformity, disintegration and dissolution 
characteristics.  They may however differ in containing different excipients. 
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Therapeutic equivalence: 
 It indicates that two or more drug products that contain the same therapeutically 
active ingredient elicit identical pharmacological effects and can control the disease to the 
same extent. 
Types of Bioequivalence studies:4 
 In vivo studies. 
 In vitro studies. 
In Vivo Studies:  
The following points are used in assessing the need for in vivo studies: 
 Oral immediate –release products with systemic action. 
 Indicate for serious conditions requiring assured response. 
 Narrow therapeutic margin. 
 Pharmacokinetics complicated by absorption lesser then 70% or nonlinear 
kinetics, pre-systemic elimination grater then 70%. 
 Unfavorable physiochemical properties like low solubility, metastable 
conditions. 
 Non-oral immediate release products. 
 Modified release products with systemic action.   
In Vitro Studies: 4 
 If none of the above criteria is applicable, comparative in intro dissolution studies 
will suffice. In vitro studies are conducted in cases where. 
 The product is intended for topical administration. (Cream, ointment gel) for local 
effect.  
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 The product is for oral administration but not intended to be absorbed(antacid or 
radio opaque medium). 
 The product is administered by inhalation as a gas or vapor. 
STUDY DESIGN17 
Bioequivalence Experimental design:4 
     The various types of test designs that are usually employed in clinical trial, 
bioavailability and bioequivalence studies. 
 Completely randomized design. 
 Randomized block designs. 
 Replicated measures cross over and carry over designs. 
 Latin cross over designs. 
 Replicated cross over designs. 
 2×2 crossover design. 
 Four-sequence and two –period design. 
 Two –sequence and four –period design. 
 Four –sequence and four-period design. 
 Two –sequence and three-period design. 
 Crossover design for three medications(Williams’  design)               
 Crossover design for four medications (Williams’ design) 
 
Basically two types of design are possible, those is parallel and cross over design. 
The major difference between these designs is the way they deal with intersubject 
variability. Intersubject variability is a measure of the difference between subjects. Both 
types of variability are present in each trial, but in the cross over design the intersubject 
Review Of Literature 
 
INSTITUTE OF PHARMACOLOGY, MMC Page 12 
 
variability is eliminated. The subjects function as his or hers own control and a difference 
between formulations within one person is only influenced by the (non) random 
variability. This makes the cross over much more efficient in terms of sample size. 
At the same time when there are two formulations, then the trial is also a two 
period trial. In the first period, 50% of the volunteers receive product A or reference and 
50% will receive product B or test. In the second period, the order is reversed 
Significance of Bioequivalence studies: 
  If a new product is intended to be a substitute for an approved medicinal product 
as a pharmaceutical equivalent or alternative, the equivalence with this product should be 
shown or justified. In order to ensure clinical performance of such products, 
bioequivalence studies should be performed. 
  Bioequivalence studies are conducted if there is a risk of bio-in equivalence or 
risk of pharmacotherapeutic failure or diminished clinical safety. Bioequivalence studies 
compare both the rate and extent of absorption of various multisource drug formulations 
with the innovator product on the basis that if two formulations exhibit similar drug 
concentration –time profiles in the blood/plasma, they should exhibit similar therapeutic 
effects. 
              The situations where bioequivalence studies are required are when the proposed  
marketed dosage form is the different from that used in pivotal clinical trials, when 
significant change are made in the manufacturer of the marketed formulation and when a 
new generic formulation is tested against the innovator’s marketed product. 
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IMPORTANCE OF BA/BE STUDIES18 
• No clinical studies have been performed in patients with the Generic Product to 
support its Efficacy and Safety. 
• With data to support similar in vivo performance (=Bioequivalence) Efficacy and 
safety data can be extrapolated from the innovator product to the generic product. 
• Keeping in view the health-care cost, the pharmaceutical companies are 
manufacturing and marketing cheaper generic drug products. 
• It is vital for the regulatory authorities of every country to ensure the efficacy and 
safety of these generic formulations. 
• Carefully planned and designed bioequivalence studies are the only way to ensure 
uniformity in standards of quality, efficacy and safety of pharmaceutical products. 
• The concept of bioequivalence forms the basis for approval of generic application, but 
it may also be applicable to hybrid application, extensions and variation applications, 
and to different formulations used during the development of a new medicinal product 
containing a new chemical entity. 
• Hybrid applications rely on the results of preclinical tests and clinical trials of an 
approved reference medicinal product and include new data.  These new data may 
include bioequivalence or comparative bioavailability data. 
• Applications for extensions such as additional dosage forms, new strengths, new 
routes of administration often need support of bioequivalence in order to bridge data 
from the authorized reference medicinal product. 
• During development of New Chemical Entity (NCE), the principle of bioequivalence 
may be applied in order to bridge data between different formulations e.g., between a 
formulation used in the pivotal clinical studies and the to-be-marketed formulation. 
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• Variations for a change in comparison or for significant manufacturing changes, 
which may affect drug bioavailability, may also require support of bioequivalence 
studies. 
•  Not only oral dosage forms such as tablets, capsules, and liquids, generic versions of 
other dosage forms, such as injections patches, inhalers, and others must also meet a 
bioequivalence standard. 
• Sometimes, the form that was originally tested is modified for commercial reasons.  
For example, tablets may need to be made sturdier, flavoring or coloring may be 
added or changed, or inactive ingredients may be changed to increase consumer 
acceptance 
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DRUG PROFILE 
TENOFOVIR 
 Tenofovir belongs to a class of antiretroviral drugs known as nucleotide analogue 
reverse transcriptase inhibitors(NtRTIs), which block reverse transcriptase, an enzyme 
crucial to viral production in HIV-people and now it has been developed highly active 
against Hepatitis B virus.10, 19 
Tenofovirdipivoxilfumarate is a prodrug   of  Tenofovir,  Its   chemically 
(9-[(R)[[bis(isopropoxycarbonal)oxy]methoxy]phosphinyl]methoxy]propyl]adenine      
fumarate 
Molecular Weight: 
                635.52. 
Molecular Formula: 
               C19 H30 N5 O10 P.C4 H4 O4 
Structural Formula: 
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Physical properties: 
 Tenofovirdisoproxilfumarate is a white to off white crystalline powder with a 
melting point 113-115C and it is soluble in water. 
Formulation: 
 Oral or enteral route is the most commonly employed route for drug 
administration as it is convenient, and economical. Tablets, pills, capsules, film coated, 
enteric coated and modified release formulations are some of the commonly available 
solid oral dosage forms designed according to its purpose. 
Film coated tablet: 20 
 Film coated tablets were developed as an alternative procedure to 
preparation of coated tablets. 
 Film coated tablets better mechanical strength of the coating based on 
elasticity and flexibility, it is improve the disintegration time. 
 To mask the taste odor (or) color of the drugs. 
 To provide physical and chemical protection for the drugs. 
 To avoid chemical incompatibilities  
Tenofovir Pathway19 
 
 Tenofovir is taken up into the cell and is subsequently phosphorylated first by 
adenylate kinases and then by nucleoside diphosphate kinases into tenofovirdiphosphate. 
Tenofovirdiphosphate is an analogue of deoxyadenosine triphosphate (dATP) and 
competes with dATP for binding to the viral DNA polymerase and subsequent 
incorporation into the growingDNA strand. Once incorporated into the DNA, tenofovir 
causes chain termination, thus preventing viral replication 
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Pharmacodynamic properties: 
 Tenofovirdisoproxilfumarateis an oral prodrug of tenofovir, and an acyclic 
nucleoside phosphonatediesteranalog of adenosine monophosphonate. Tenofovir requires 
initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylations by 
cellular enzymes to form tenofovirdiphosphate. Tenofovirdiphosphate is a weak inhibitor 
of mammalian DNA polymerases α,β, and mitochondrial DNA polymerase γ. 9 
Mechanism of action:9, 10 
 Tenofovirdisoproxilfumarate is an oral prodrug after conversion of 
Tenofovirdiphosphate inhibits the activity of HIV-1 reverse transcriptase by competing 
with the natural substrate deoxyadenosine 5’-triphosphate and after incorporation into 
DNA, by DNA chain termination. Specifically, the drugs are analogues of the naturally 
occurring deoxynucleotides  needed to synthesize  the viral DNA and they compete with 
the natural deoxynucleotides for incorporation into the growing viral DNA chain. 
However, unlike the natural deoxynucleotides substrates, NRTIs and NtRTIs 
(Nucleoside/Nucleotide Reverse Transcriptase Inhibitors) lack a 3’-hydroxyl group on the 
deoxyribose moiety. As aresult, following incorporation of an NRTI or an NtRTI, the 
next incoming deoxynucleotide cannot form the next 5’3’ phosphodiester bond needed to 
the DNA chain.  Thus, when an NRTI or NtRTIs is incorporated, viral DNA synthesis is 
halted, a process known as chain termination. All NRTI and NtRTIs are classified as 
competitive substrate inhibitors. 
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Data pertaining to HIV: 
 HIV antiviral activity in vitri: The concentration of tenofovir required for 50% 
inhibition(EC50) of the wild-type laboratory strain HIV-1 IIIB is 1-6 µmol/1 in lymphoid 
cell lines and 1.1µmol/1 against primary HIV-1 subtype B isolates in PBMCs. Tenofovir 
is also active against HIV-1 subtypes A, C, D, E, F, G and O and against HIVBaL in 
primary monocyte/macrophage cells. Tenofovir shows activity against HIV-2, with EC50 
of 4.9µmol/l in MT cells. 
Data pertaining to HBV: 
 HBV antiviral activity in vitro: The in vitro antiviral activity against HBV was 
assessed in the HepG 2.2.15 cell line. The EC50 values fortenofovir were in the range of 
0.14 to 1.5µmol/1 with CC50 (50% cytotoxicity concentration) values >100µmol/1. 
Pharmacokinetic properties: 
Absorption:  
 Following oral administration of tenofovirdisoproxilfumarate to HIV infected 
patients, tenofovirdisoproxilfumarate is rapidly absorbed and converted to tenofovir. 
Administration of multiple doses of tenofovirdisoproxilfumarate with a meal to HIV 
infected patients resulted in mean (%CV) tenofovirCmax, AUC0-∞, and Cmin values of 
326 (36.6%) ng/ml, 3,324 (41.2%) ng·h/ml and 64.4 (39.4%) ng/ml, respectively. 
Maximum tenofovir concentrations are observed in serum within one hour of dosing in 
the fasted state and within two hours when taken with food. The oral bioavailability of 
tenofovir from tenofovirdisoproxilfumarate in fasted patients was approximately 25%. 
Administration of tenofovirdisoproxilfumarate with a high fat meal enhanced the oral 
bioavailability, with an increase in tenofovir AUC by approximately 40% and Cmax by 
approximately 14%. Following the first dose of tenofovirdisoproxilfumarate in fed patients, the 
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median Cmax in serum ranged from 213 to 375 ng/ml. However, administration of 
tenofovirdisoproxilfumarate with a light meal did not have a significant effect on the 
pharmacokinetics of tenofovir. 21 
Distrbution: 
Following intravenous administration the steady-state volume of distribution of 
tenofovir was estimated to be approximately 800 ml/kg. After oral administration of 
tenofovirdisoproxilfumarate, tenofovir is distributed to most tissues with the highest 
concentrations occurring in the kidney, liver and the intestinal contents (preclinical 
studies). In vitro protein binding of tenofovir to plasma or serum protein was less than 0.7 
and 7.2%, respectively, over the tenofovir concentration range 0.01 to 25 µg/ml.22 
Tenofovirdisoproxilfumarate (DF) at a dose of 300 mg has a volume of 
distribution of 0.813 L/kg 
Metabolism: 
In vitro studies have determined that neither tenofovirdisoproxilfumarate nor tenofovir 
are substrates for the CYP450 enzymes. Moreover, at concentrations substantially higher 
(approximately 300-fold) than those observed in vivo, tenofovir did not inhibit in vitro drug 
metabolism mediated by any of the major human CYP450 isoforms involved in drug 
biotransformation (CYP3A4, CYP2D6, CYP2C9, CYP2E1, or CYP1A1/2). 
Tenofovirdisoproxilfumarate at a concentration of 100 µmol/l had no effect on any of the 
CYP450 isoforms, except CYP1A1/2, where a small (6%) but statistically significant reduction in 
metabolism of CYP1A1/2 substrate was observed. Based on these data, it is unlikely that 
clinically significant interactions involving tenofovirdisoproxilfumarate and medicinal products 
metabolised by CYP450 would occur. 
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Elimination 
Tenofovir is primarily excreted by the kidney by both filtration and an active 
tubular transport system with approximately 70-80% of the dose excreted unchanged in 
urine following intravenous administration. Total clearance has been estimated to be 
approximately 230 ml/h/kg (approximately 300 ml/min). Renal clearance has been 
estimated to be approximately 160 ml/h/kg (approximately 210 ml/min), which is in 
excess of the glomerular filtration rate. This indicates that active tubular secretion is an 
important part of the elimination of tenofovir. Following oral administration the terminal 
half-life of tenofovir is approximately 12 to 18 hours. 
Studies have established the pathway of active tubular secretion of tenofovir to be 
influx into proximal tubule cell by the human organic anion transporters (hOAT) 1 and 3 
and efflux into the urine by the multidrug resistant protein 4 (MRP 4). 
Adverse Effects: 19 
 Assessment of adverse reaction for tenofovirdisoproxilfumarate is based on safety 
data from clinical studies and post marketing experience. 
 HIV-clinical study data is based on , 
Lactic acidosis and severe hepatomegaly with steatosis. 
Reduced Bone Mineral Density- Clinical trials in HIV-1 infected children    . 
 Hepatitis B –clinical study data is based on chronic condition exacerbations of 
hepatitis 
 Gastrointestinal ( anotexia, nausea, vomiting, diarrhea) 
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Clinical uses of Tenofovir: 
HIV-1 infection: 
 Tenofovir is indicated in combination with other antiretroviral agents for the 
treatment of HIV-1 infected in adults and paediatric patients 2 years of age and older. 
 Tenofovir used to treat HIV-1 infected person as combination therapy according 
to NACO second line drugs (TENOFOVIR+ABACAVIR )and it is effective in 
lamivudine resistant cases. 
Chornic Hepatitis B 
 Tenofovir is indicated for the treatment of chronic hepatitis B in adults and 
paediatric patients 12 years of age and older. 
Compensated liver disease, with evidence of active viral replication, persistently 
elevated serum alanine aminotransferase (ALT) levels and histological evidence of active 
inflammation and/or fibrosis 
 Finally, the purpose of BA/BE studies is to find whether the test formulation gives 
a blood profile identical to the reference standard product or not.  Due to the limitation in 
sampling techniques the resultant blood-levels curve is influenced by both the number 
and duration of blood samples obtained in any study.  Unfortunately, due to biological 
and experimental variations, some differences always exist and it is necessary to ascertain 
whether these differences are occurrences or due to actual differences in treatment 
administration to the subjects.  Statistical methods are used to evaluate the data on order 
to identify the different sources of variation and if possible to measure the contribution of 
each identified variable and isolate the specific observation 
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 The conclusion is that clinical studies are not the optimum choice for comparison 
of formulations and an alternative method had to be developed, which is the 
pharmacokinetic approach. The advantage of a pharmacokinetic approach is the definition 
of the plasma/serum concentration of the drug.  These bioequivalence studies solve many 
of the problems encountered with clinical testing and they lead to the development of 
more advantageous clinical trials benefiting the manufacturer and the patien 
STUIDES PERFORMED IN TENOFOVIR 
1. Single dose Bioequivalence of a new fixed –dose combination tablet containing 
Tenofovirdisoproxilfumarate and lamivudine, bioequivalence study was 
conducted by Feleder Ethel et al. This study a randomized, single centre, open 
label, single dose two way crossover bioequivalence study in 40 healthy adults 
subjects was conducted.  In this study plasma levels of tenofovir and lamivudine 
were determined by a validated   HPLC/Fluoresence assay and validated 
HPLC/UV assay. The study indicated that the test preparation was bioequivalent 
to the reference product.21 
 
2.
 Pharmacokinetic study of TenofovirDisoproxilFumarate combined with Rifampin 
in healthy volunteers, this study was conducted by J.A.H. Droste. Tenofovir was 
studied in combination with rifampin in 24 healthy subjects in a multiple –dose 
,open label , single –group two period study.  According to this study co –
administration of rifampin and tenofovir  did not  result in changes in the values of 
the tenofovir pharmacokinetic parameters and it was found that the test and the 
reference products were bioequivalent.22 
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3.
 Manish Yadav et al. investigated the selective determination of antiretroviral 
agents Tenofovir, Emtricitabine , and lamivudine in human plasma by a LC-MS-
MS method for a Bioequivalence study in healthy Indian subjects . The method is 
fully validated for its sensitivity, selectivity, accuracy, and precision. It is 
successfully applied to a bioequivalence study of [300(TFV) +200(FTC) + 
300(3TC)] mg tablet formulation in 43 healthy human subjects under fasting 
conditions. The study indicated that the test preparation was bioequivalent to the 
reference preparation.23 
 
4.
 Kumar pradeep et al validated HPTLC method for the determination of tenofovir  
as bulk drug and pharmacokinetics dosage form. This method was validated 
according to various ICH parameter like linearity, accuracy, precision, limits of 
detection and limits of quantification. The test and reference products were found 
to be a chemically equivalent.24 
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OBJECTIVES 
1. To compare the bioavailability of tenofovir film coated tablets with the 
conventional dosage form given in equivalent doses. 
 
2. To estimate the serum concentration of film coated tablet oftenofovir 
(test) and conventional tenofovir (reference) through bio-analytical 
method validation using LC-MS/MS. 
 
3. To monitor the adverse events and ensure safety of the subjects. 
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MATERIALS AND METHODS 
       The study was conducted at Azidus Laboratories Ltd., located at Rathnamangalam, 
vandalur, Chennai-48 in collaboration with Institute of Pharmacology, Madras Medical 
College Chennai. 
Study Design: 
 An open label, balanced, randomized, two treatment, three sequence, three period, 
single dose,  cross over,  Semi-replicate, oral bioequivalence pivotal studyunder  fed 
conditions. 
Study Type: 
                 Prospective Bioequivalence study 
Study centre: 
Azidus Laboratories Ltd., located at Rathnamangalam, vandalur, Chnnai-48 in        
collaboration with Institute of Pharmacology, Madras Medical College Chennai. 
Sample Size: 36. 
Study Population: 
   Healthy adult, male subjects 
Study Period: 
            03 period-minimum washout period 7 days 
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Study Duration: 
            6 months. 
Ethical consideration: 
 The protocol was prepared and submitted to the Independent Ethical Committee, 
Azidus Laboratories Ltd, Chennai and approval was obtained. 
 The volunteers were intimated by the word of mouth and were asked to come to 
Azidus laboratories screening room. They were explained about the study procedure and 
purpose. Written informed consent was obtained from those who were willing to 
participate in the study. Then, they underwent screening by medical history, clinical 
examination and laboratory investigations. 
Inclusion Criteria: 
 Age: 20-45 years.  
 Gender: Healthy adult male subjects. 
 Body Mass Index:  18.50 – 30.00 Kg/m2 
 Subject should be non-vegetarian 
 Subject with no evidence of any disease during screening. 
 Subject with screening laboratory values in normal limits. 
 Negative alcohol breath analysis(to be performed on day of check in during each 
period and during ambulatory) 
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Exclusion Criteria: 
 Subject incapable of understanding the informed consent.  
 History of any major surgical procedure in the past 3 months. 
 History of diabetes mellitus, tuberculosis and systemic hypertension.  
 History of dysphagia. 
 Vegetarian. 
 History of any medical disorder that is of significance in the investigator’s 
opinion.  
 History of hypersensitivity to Tenofovir and related drugs or excipients in the 
formulation (if the excipients are known).   
 History of allergy to vegetables and / or food substances and / or any other 
manifestations suggestive of hypersensitivity reactions 
 Present or past history of intake of drugs* which potentially modify kinetics / 
dynamics of Tenofovir or any other medication judged to be clinically significant 
by the investigator.  
 Consumption of grapefruit / its products within 10 days prior to the start of study. 
 Intake of any prescription drug or over-the counter (OTC) drugs within  4 weeks 
prior to study and / or intake of any drug* in the past that could affect the kinetics 
or dynamics of Tenofovir in view of investigator. 
 Subject with clinically significant abnormal values of laboratory parameters.  
 Subject who had participated in any other clinical study during the last 3 months 
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 Subject who had bled in the past 3 months from the date of start of study either 
for blood donation or for any other reason.   
 History of habituation to coffee, tea or other xanthine containing products and 
inability to withhold the intake during the - in house - stay.  
*Hepatic microsomal enzyme inducers (which can reduce the systemic 
bioavailability)Barbiturates, carbamazepine, Ethanol, inhalational anesthetics, 
Griseofulvin, phenytoin, primidone, Rifampicin,   
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SCREENING LABORATORY TEST 
The following laboratory investigations were performed at screening. 
Screening Laboratory tests 
Biochemistry Haematology 
 Blood Sugar-Random 
 Serum Urea   
 Creatinine   
 Total Cholesterol  
 Triglycerides(non-fasting) 
 Serum Bilirubin (Total) 
 Serum Bilirubin (Direct) 
 Serum Bilirubin(Indirect) 
 Uric acid  
 ALT    
 AST    
 Alkaline Phosphatas  
 Total Protein  
 Albumin   
 Globulin   
 A/G Ratio   
 LDH    
 Gamma GlutamylTransferase 
 Sodium   
 Potassium 
 Chloride 
 Calcium  
 Beta-HCG (serum pregnancy test) 
(in case of females) 
 
 Total W.B.C. count  
 Differential leukocyte count 
 Total R.B.C. count 
 Haemoglobin 
 Haematocrit (PCV) 
 Platelets count 
 ESR  (1st Hour) 
 Blood Grouping & Rh Typing 
 
Urine (routine analysis) 
 Turbidity        
 Colour 
 RBCs 
 Bilirubin  
 Urobilinogen 
 Ketone 
 Protein  
 Nitrite 
 Glucose  
 pH  
 Specific Gravity 
 Microscopic Examination 
(Leucocytes & Epithelial cells) 
Serology 
 HIV 1 & 2 
 Hepatitis B surface antigen 
 Hepatitis C antibody 
 Syphilis 
Others 
 Chest X ray PA view  
 ECG in 12 leads  
 Urine drugs of abuse* 
 Alcohol breath analysis test 
 Urine pregnancy test (in case of 
females)  
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STUDY PROCEDUE: 
        The study was conducted after obtaining approval from the Independent Ethics 
Committee (IEC). Prospective volunteers were explained about the study procedure and 
purpose. After obtaining written informed consent from willing participants, they were 
subjected to screening by history, clinical examination and laboratory investigations.  
HOUSING: 
           In all periods, the subjects were housed in the clinical facility, minimum 12 hours 
prior to dosing until 48 hours post dose. All subjects were maintained in a fasting state for 
a minimum 8 hours prior to dosing.  
 Subjects were admitted at least 12 hours before the proposed time of drug 
administration. 
 After drug administration, subjects had to stay for  atleast  48  hrs. The duration of 
stay in each period (from subject check-in to check-out) was 60hrs,  spreading 
over a period of 4 days. 
DIET& WATER: 
 After check-in, subjects will receive standard dinner after which they will be 
required to fast overnight for at least 8 hours. 
 .Being a fed study, subjects will be served a high fat, high calorie breakfast 30 
minutes prior to dosing 
 The subjects are required to consume all the food served in the high fat, high 
calorie breakfast. 
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 The subjects will receive standard food approximately at 04.00, 08.00, 12.00, 
24.00, 28.00, 32.00 and 36.00 hrs post dose 
 Drinking water will not be permitted one hour before dosing and until one hour 
post-dose, at all other times drinking water will be permitted ad libitum.  
 
RANDOMIZATION: 
Study subjects will receive any of the two investigational products in each of the 
study periods. The order of receiving the test and reference product for each subject will 
be according to the randomization schedule. The randomization schedule will be 
generated by using SAS®. Each study subject will be randomly assigned to one of the 
following dosing sequences. 
 
 Period I Period II Period III 
Sequence I T R R 
Sequence II                         R T R 
Sequence III                         R R T 
      * T- Test 
 * R- Reference 
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PERIOD I: 
Pre-Dosing Day: 
The subjects who fulfilled the selection criteria were enrolled in the study. The 
subjects were asked to come one day prior to the study for admission. On admission the 
vital parameter were recorded. They were provided with standard food throughout the 
study period. The subjects were made of fast for 8 hours prior to dosing. 
 
Fed Breakfast Menu: 
S. No. Session  Meal Menu Items with unit 
1 
 
Break fast 
 
Toasted Bread + butter 2 slices + 20g butter 
Fried Egg  2 No.s (70g) 
French Potato fries 75 g 
Milk with Sugar 1 tsp 240 ml 
Fried Chicken  100g 
 
Dosing Day: 
 At 8 0’ clock in the morning on the dosing day, blood sample was taken from the 
anterior cubital vein of the forearm for estimating the pre dose concentration.Being a fed 
study, subjects will be served a high fat, high calorie breakfast 30 minutes prior to dosing. 
At 9 0’ clock dosing was done as per randomization schedule for 36 subjects with two 
minute intervals between the subjects. 
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 During dosing, tablet were given orally as asingle  dose of Test product (T) or 
Reference product (R) will be administered to subjects in sitting posture at fixed time 
points starting from 09.00 AM, in each period as per the randomization schedule. Study 
medication will be administered with 240 ± 02 ml of water, at ambient temperature in 
each period by trained personnel in the presence of Investigator/study physician. This 
activity will be followed by mouth check to assess the compliance to dosing. The subjects 
were asked to be sitting posture for first four hours following drug administration and 
were asked not to do any activity. Subjects were enquired for their well-being after drug 
administration by a questionnaire. Vitals signs were checked at 0, 2,4,6,12,and 24 hours 
post dose. Adverse events were monitored according to its severity. At the end of 60 
hours, the volunteers were discharged. They were asked to come again for admission after 
a 07 day washout period for period II. 
Washout period:         7 days. 
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PERIOD II:  
Per-dosing day: 
 The subjects enrolled were instructed to come one day prior to the study day 
for admission. 
 On admission, the vital sings were recorded. 
 Dinner was provided and the subjects fasted overnight for atleast 8 hours prior 
dosing. 
Dosing Day: 
 8 AM an intravenous cannula was inserted in forearm vein for blood 
collection and pre- dose blood sample was collected for estimating the pre 
dose concentration. Vital sings were recorded. 
 Being a fed study, subjects will be served a high fat, high calorie breakfast 30 
minutes prior to dosing. 
 9 AM Dosing was done as per randomization schedule. One tablet of 
Tenofovir 245 mg either test or reference was administered with 240 ml of 
water under direct observation  
 The remaining procedure were followed as same period I 
 At the end of 48 hours, the volunteers were discharged. 
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PERIOD III : 
 After completion of the second period, the subjects were asked to come again 
for admission after 7-days wash out period. The remaining procedures were 
followed in the same way as in period I. 
 After completion of the study, blood samples were collected for drug analysis 
to confirm that the drug has been eliminated completely from the 
physiological system. 
 The laboratory post study values were compared with per-study laboratory 
test values. If any clinically significant changes were seen, the subjects were 
followed up and appropriate medical treatment provided.  
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METHODS OF BLOOD SAMPLE COLLECTION 
Before dosing: 
            Blood samples were collected through an indwelling cannula placed in forearm 
vein. If there was difficulty in obtaining through intravenous cannula, blood samples were 
obtained by direct venous puncture. 
         While collecting blood sample, after insertion of the cannula and after withdrawal of 
every sample of blood, 0.5 ml of heparinised saline (10 IU/ml) was injected to maintain 
the potency of cannula. After discarding the initial 0.5 ml of blood, the required volume 
of blood was collected. Blood samples were collected using pre-labelled vials containing 
K3 EDTA. 
In each period 21 samples were collected from each subject as per the following 
schedule.The pre-dose samples werecollected within 01 hour prior to drug dosing. 
The post-dose samples were  collected at 00.00 hour (pre-dose), 00.25, 00.50, 
00.67, 01.00, 01.25, 01.50, 01.75, 02.00, 02.25, 02.50, 02.75, 03.00, 04.00, 06.00, 08.00, 
12.00, 16.00, 24.00, 36.00, 48.00 and 72.00 hours post dose (Total of 22 samples - 4 ml 
each). First 21 samples will be collected as in-house samples and 72.00 hr sample will be 
collected as ambulatory sample. First 19 blood samples will be collected through an 
indwelling cannula placed in a forearm / arm and remaining 3 blood samples will be 
collected through direct vein puncture.The post-dose samples will be collected within 2 
minutes of the scheduled time where the end time of collection to the nearest minute 
would be recorded. Any deviations above two minutes would be recorded as blood 
sampling deviation. 
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Total Blood Withdrawn 
The total volume of blood draw from each subject during the study will not 
exceed 308.5 ml.[22x4mlx3 = 264 ml] + [0.5 ml discarded for first 19 blood draws 
19x0.5mlx3 = 28.5 ml] + [screening =10 ml] + [post study safety evaluation = 6 ml] = 
308.5 ml. 
Sample Handling and Processing: 
Blood samples collected during the study will be kept for 30 minutes under room 
temperature and then centrifuged at 4000 rpm for 10 minutes at 4 ± 2°C. Serum will be 
separated into double aliquots and stored at about -20°C or colder in Clinical unit. The 
first aliquot will have 1.0 ml of serum and the second aliquot, the remaining serum. 
Post study procedure: 
Following tests were performed at the end of period III, 
1. Hematology —        Hemoglobin in %, Platelet Count,PCV. 
2. Liver functions—         SGOT, SGPT 
3. Serum Chemistry —    Random Blood Sugar, Urea, Creatinine.  
Physical examination, vital parameter assessment and wellbeing assessment were 
performed to all study subjects during each period  & during check-out, to ensure safety 
of the study. 
The laboratory post study values were compared with pre-study laboratory test 
values. If any clinically significant deviations were seen, the subjects were followed up 
and appropriate medical care was provided. 
  
                                                                            Materials And Methods 
 
INSTITUTE OF PHARMACOLOGY, MMC Page 39 
 
BIOANALYTICAL METHODOLOGY25,26 
A validated Liquid Chromatography and Mass Spectroscopy   (LC-MS/MS) 
method was employed for the estimation of Tenofovir in serum. Samples with drug 
concentration greater than upper limit of the validated range of the analysis were diluted 
using the appropriate drug free biological fluid and reanalysed by dilution integrity 
testing. 
Incurred sample analysis was carried out for a minimum 10% of total study 
samples. Samples, which were below the lower limit of quantification (LLOQ) was 
reported as below limit of quantification (BLQ).  
As first 36 subjects completed all the three periods of the study Standby subjects were not 
considered for Bioanalysis, Pharmacokinetic and Statistical Analysis as per the approved 
protocol. 
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INSTRUMENT 
Mass Spectrometric Conditions 
Agilent Infinity 1290-Binary Pump, Auto Sampler, Degasser, Agilent 6460 Triple 
Quad LC/MS. 
S.No Parameter 
1 Ion Source ESI+Agilent Jet Stream 
2 Polarity                        Positive 
3 Gas Temp (°C) 300 
4 Gas Flow ( l/min) 5 
5 Nebulizer (psi) 45 
6 Sheath Gas Temp (°C) 350 
7 Sheath Gas Flow ( 1/min ) 11 
8 Capillary (V) 4000 
9 Nozzle Voltage (V) 500 
 
 
Multiple Reacting Mode Conditions 
S. No. Parameter Tenofovir AdefovirDipivoxil 
1 Precursor Ion 288.1              274.1 
2 Product Ion 176.1 162 
3 Fragmentor (V) 105 100 
4 Collision Energy (V) 25.00 30.00 
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Chromatographic Conditions: 
 
S.No. Parameters   
1 Column Synergi Polar-RP, 150x2mm, 4µ 
2 Mobile Phase 
0.2% of Formic Acid in water: 
Methanol/95:5(v/v)  
3 Flow Rate 0.3 mL/minute  
4 Autosampler Temperature 5ºC 
5 Column Oven Temperature 30ºC 
     6 Injection volume 2µL 
7 Run Time  4mins 
 
VALIDATION METHOD OF TENOFOVIR: 
Bioanalytical procedure: 
             Materials Required: 
 Tenofovir (Working Standard) 
 Adefovir (Internal Standard) 
 Sodium Carbonate  (General Reagent) 
 Methanol (HPLC Grade) 
 Formic Acid (General Reagent) 
 Milli-Q water(Type I) 
 Cartridge MAX 30mg/1cc 
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Preparation of Reagents and Solutions 
Preparation of Diluent : [Methanol: Water / 50:50 (v/v)] : 
Transfer 50 mL of Methanol and 50mL of Type I Milli-Q water into 100 mL reagent 
bottle, mix well and sonicate it for 5 minutes.  
Preparation of 50 mM Sodium Carbonate: 
Weigh exactly 0.5299 gm of Sodium Carbonate transfer into a 100mL reagent bottle. Add 
100 mL of Type 1 milli Q water and filter through 0.2 µm membrane filter sonicate for 10 
minutes. 
Preparation of  2% Formic acid in Methanol: 
Transfer 2mL of Formic acid into 100mL of Reagent bottle which containing 98 mL of 
Methanol. Mix well the reagent bottle and sonicate for 5 minutes.  
Preparation of 0.2% of Formic Acid in water: 
Transfer 2mL of Formic Acid into 1000mL of Reagent bottle which      containing 998ml 
of Water. Mix well the reagent bottle and sonicate for 5 minutes. 
Preparation of Mobile phase [0.2% of Formic Acid in water:Methanol/95:5(v/v)]  : 
Transfer 950mL of above solution A in clean 1000mL reagent bottle and add 50mL of 
Methanol. Mix well and  sonicate for 5 minutes.  
Preparation of Needle Wash: (Water: Methanol/ 90:10(v/v)): 
 Transfer the 900ml of Water in 1000ml of reagent bottle containing 100ml of Methanol 
and mix well the reagent bottle.  
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STOCK SOLUTION PREPARATION: 
Preparation of  Tenofovir Stock Solution: 
Weigh accurately about 10 mg of Tenofovir and transfer into a 10mL volumetric flask. 
Dissolve it in Type I Milli-Q Water and make up the volume with the same to produce a 
solution of 1mg/mL strength of Tenofovir.  
Preparation of AdefovirDipivoxil (IS) Stock Solution: 
 
Weigh accurately about 10mg of AdefovirDipivoxil and transfer into a 10 mL volumetric 
flask. Dissolve it in Type I Milli-Q Water and make up the volume with the same to 
produce a solution of 1mg/mL strength of AdefovirDipivoxil.  
Note:  Actual concentration of Stock Solutions may vary depending upon the amount of 
compound weighed and the purity of the compound 
Preparation of Tenofovir CC Samples Stock Dilutions: 
 
From Tenofovir stock solution, diluents ranging from 472.7268 ng/mL- 43290.00ng/Ml 
with (methanol : water/ 50:50), v/v provided in the Table No.1 were prepared. 
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Table No. 1 - Stock Dilutionfor Tenofovir Calibration Standards 
 
Initial Stock 
Conc. 
(ng/ml) 
Volume stock 
taken(mL) 
Volume Diluent 
added(mL) 
Total volume of 
solution(mL) 
Final stock 
Conc 
(ng/ml) 
962000.0000 0.45 9.55 10.000 43290.0000 
43290.0000 8.00 2.00 10.000 34632.0000 
34632.0000 6.50 3.50 10.000 22510.8000 
22510.8000 6.00 4.00 10.000 13506.4800 
13506.4800 4.00 6.00 10.000 5402.5920 
5402.5920 5.00 5.00 10.000 2701.2960 
2701.2960 3.50 6.50 10.000 945.4536 
945.4536 5.00 5.00 10.000 472.7268 
 
 
PREPARATION OF CALIBRATION STANDARDS AND QUALITY CONTROL 
SAMPLES 
 
TenofovirCalibration Standards in Human Serum:  
    From Tenofovir CC Stock Dilutions made as per Section 5.4.2, prepare Calibration 
Standards in Human Serum by ranging from 9.4545ng/mL – 865.8000 ng/mL, as 
provided in the Table No.2. 
Note:  Stock concentrations may vary depending upon the amount of compound weighed 
and the purity of the compound 
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Table No.2 Tenofovir calibration standards in Human serum 
S.No 
Initial 
Solution 
ID 
Initial 
Stock 
Conc.   
(ng/mL) 
Volume 
of Stock 
taken          
(mL) 
Volume 
of 
Serum 
added 
(mL) 
Total 
Volume 
of Final 
Solution 
(mL) 
Final 
Stock 
Conc.           
(ng/mL) 
Final 
solution 
ID 
1 SS1 43290.0000 0.200 9.800 10.000 865.8000 STD-8 
2 SS2 34632.0000 0.200 9.800 10.000 692.6400 STD-7 
3 SS3 22510.8000 0.200 9.800 10.000 450.2160 STD-6 
4 SS4 13506.4800 0.200 9.800 10.000 270.1296 STD-5 
5 SS5 5402.5920 0.200 9.800 10.000 108.0518 STD-4 
6 SS6 2701.2960 0.200 9.800 10.000 54.0259 STD-3 
7 SS7 945.4536 0.200 9.800 10.000 18.9091 STD-2 
8 SS8 472.7268 0.200 9.800 10.000 9.4545 STD-1 
 
Stock concentrations may vary depending upon the amount of compound weighed 
and the purity of the compound, but it should not be less than 9.4545 ng/mL and not more 
than 865.800 ng/mL. 
Preparation of AdefovirDipivoxil (IS) Stock Solution: 
Weigh accurately about 10mg of AdefovirDipivoxil and transfer into a 10 mL volumetric 
flask. Dissolve it in Type I Milli-Q Water and make up the volume with the same to 
produce a solution of 1mg/mL strength of AdefovirDipivoxil. Fill the respective ‘SOP 
Forms’ and label the solution as per relevant SOP. 
Note:  Actual concentration of Stock Solutions may vary depending upon the amount of 
compound weighed and the purity of the compound. 
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Preparation of AdefovirDipivoxil (IS) Stock Dilutions: 
 From AdefovirDipivoxil Stock Solution, as per Section 5.3.2, prepare Working 
Concentration of the 
Table No. 3 – Stock Dilution for AdefovirDipivoxil 
 Internal Standard Solution (about 50 µg/mL) as provided in the Table No.4. 
QUALITY CONTROL (QC) SAMPLES: 
Preparation of Tenofovir QC Samples Dilutions: 
From Tenofovir Stock Solution made as per Section 5.3.1, prepare Stock Dilutions 
ranging from 490.2352ng/mL –33670.0000 ng/mL with (Methanol: Water / 50:50), as 
provided in the Table No.4. 
Table No. 4 - Stock Dilution Tenofovir Quality Control Samples: 
S.No 
Initial 
Solution 
ID 
Initial 
Stock Conc.   
(ng/mL) 
Volume 
of 
Stock 
taken       
(mL) 
Volume 
of 
Diluent 
added 
(mL) 
Total 
Volume 
of Final 
Solution 
(mL) 
Final 
Stock 
Conc.           
(ng/mL) 
Final 
solution 
ID 
1 QC STD 1 962000.0000 0.35 9.65 10.000 33670.0000 QC1 
2 QC1 33670.0000 5.20 4.80 10.000 17508.4000 QC2 
3 QC2 17508.4000 4.00 6.00 10.000 7003.3600 QC3 
4 QC3 7003.3600 2.00 8.00 10.000 1400.6720 QC4 
5 QC4 1400.6720 3.50 6.50 10.000 490.2352 QC5 
Initial 
Solution 
ID 
Initial 
Stock 
Conc.   
(µg/mL) 
Volume 
Taken       
(mL)                    
Volume 
of 
Diluent 
(mL)        
Total Volume 
of Final 
Solution  
(mL)  
Final 
Stock 
Conc.           
(µg/mL) 
Final 
solution 
ID 
STOCK 
A 1000.0000 0.500 9.500 10.0000 50.0000 
STOCK 
B 
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PREPARATION OF TENOFOVIR  QUALITY CONTROL SAMPLES  
IN HUMAN SERUM: 
TenofovirQuality Control Samples in Human Serum:   From TenofovirQC Stock 
Dilutions made as per Section 5.4.3, prepare Quality Control samples in Human Serum 
ranging from, 9.8047ng/mL – 673.4000ng /mL as provided in the Table No.5 
Table No. 5-TenofovirQuality Control samples in Human Serum 
S.No 
Initial 
Solution 
ID 
Initial 
Stock 
Conc.   
(ng/mL) 
Volume 
of 
Stock 
taken                
(mL) 
Volume 
of Serum 
added 
(mL) 
Total 
Volume of 
Final 
Solution 
(mL) 
Final 
Stock 
Conc.           
(ng/mL) 
Final 
solution 
ID 
1 QC 1 33670.0000 0.200 9.800 10.000 673.4000 HQC 
2 QC 2 17508.4000 0.200 9.800 10.000 350.1680 MQC 
3 QC 4 1400.6720 0.200 9.800 10.000 28.0134 LQC 
4 QC 5 490.2352 0.200 9.800 10.000 9.8047 LOQQC 
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SAMPLE PREPARATION 
 
Extraction Type – Liquid - Liquid Extraction27 
 Withdraw the CC/QC samples from intended storage area and keep for thawing at 
room temperature.   
 Aliquot 100 µL of sample to labeled RIA vials 
 Add 50 µL of internal standard (AdefovirDipivoxil 50µg /mL) into all the   
samples except blank and vortex. 
 Conditioning: Condition the cartridge (Oasis MAX 30mg/1cc) with 1 mL of 
methanol. 
 Equilibration: Equilibrate the cartridge with 1 mL of Type I MilliQ Water. 
 Loading: Load the Sample into Cartridge. 
 Washing I: wash the cartridge with 1 mL of 50 mM Sodium Carbonate. 
 Washing II: wash the cartridge with 1 mL of 100% Methanol. 
 Dry the cartridge 5-10 minutes. 
 Elution: Elute 2times with 300µl of elution solvent (2% formic acid inMethanol). 
 Evaporate the eluent at 40º C by using Low Volume Evaporator at 15 psi. 
 Reconstitute the dried residue with 0.2 mL of Mobile phase [0.2% of Formic Acid 
in water:Methanol/95:5(v/v)]. 
 Transfer the sample into appropriately labeled auto sampler vials and load the 
samples into LCMS/MS. 
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Tenofovir-Analytical Data Processing 
 The concentration of unknown is calculated from the following equation 
by utilizing linear regression with 1/x² as weighting factor. 
 
Y= mX+b 
 
Where,     Y = Peak area ratio of Tenofovir. 
X = Concentration of Tenofovir.  
       m = Slope of the Calibration Curve.  
 b = Intercept of the Calibration Curve 
PHARMACOKINETIC ANALYSIS 
Pharmacokinetic analysis was done by Non- compartmental method of analysis using the 
WinNonlin® Version 5.3. 
          The following pharmacokinetic parameters were calculated− 
Primary pharmacokinetic parameters: 
Cmax : 
 Maximum measured plasma concentration over the time span specified. 
AUC0-t: 
              The area under the plasma concentration versus time curve, from time zero to the 
last time point with measurable concentration, calculated by the linear trapezoidal 
method. 
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AUC₀-∞: 
 The area under the plasma concentration versus time curve, from time zero to time 
infinity. AUC0-∞ is calculated as the sum of the AUC0-t plus the ratio of the last 
measurable concentration to the elimination rate constant.  
Secondary Pharmacokinetic parameters: 
Tmax: 
Time of maximum measured plasmaconcentration.  If the maximum value occurs 
at more than one point, Tmax is defined as the first point with this value in each period.  
Kel: 
Apparent first order elimination or terminal rate constant calculated from a semi-
log plot of the plasma concentration versus time curve. 
T1/2: 
Time required for the plasma drug concentration to decrease by one half of the 
drug.   If pre-dose concentration was found to be less than or equal to 5% of mean Cmax, 
the value was considered as such for calculation. If the pre-dose concentration of a 
subject is more than 5% of Cmax, the respective subject will be dropped from 
bioequivalence analysis. 
While Pharmacokinetic data is reported, the number of points of the terminal log-
linear phase used to estimate the terminal rate constant (Kel) will be reported.  
AUC0-t shall cover at least 80% of AUC0-∞. Subjects will not be excluded from the 
statistical analysis if AUC0-t covers less than 80% of AUC0-∞.  
                                                                            Materials And Methods 
 
INSTITUTE OF PHARMACOLOGY, MMC Page 51 
 
                                           STATISTICAL ANALYSIS 
The descriptive statistics such as mean, standard deviation, geometric mean and 
coefficient of variation were reported for the relevant pharmacokinetic parameters,Cmax, 
AUC0-t and AUC0-∞ and secondary parameters, Tmax, t1/2 nadKel were estimated for both 
Test and Reference products. 
Analysis of variance (ANOVA):28, 29 
ANOVA was performed using the SAS® statistical software  (version: 9.2) 
General linear model (GLM) procedure.The Ln-transformed pharmacokinetic parameters 
(Cmax, AUC0-t and AUC0-∞) were analysed using an ANOVA model with the main effects 
of treatment, period and sequence as fixed effects and subjects nested within sequence as 
random  
           A separate ANOVA model was used to analyse each of the parameters. The 
sequence effect was tested at the 0.10 level of significance using the subjects nested 
within the sequence mean square from the ANOVA as the error term. As other main 
effects were tested at the 0.05 level of significance against the residual error (mean square 
error ) from the ANOVA as the residual error.  
             Sum of squares (Type III) was reported and probability values (P) were derived 
from it. For all analyses, effects were considered statistically significant, if the probability 
associated with “F” was less than 0.05.  
90 % Confidence Intervals(CI): 
Consistent with the two one-sided tests for bioequivalence, 90% confidence 
intervals for the difference between the test and reference means was calculated for the 
untransformed data and log transformed data. 
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          The confidence limits were expressed as percentages of the least square 
mean(LSM) of the reference product. Using the confidence limits of the above CI and the 
LSM of the reference product, an approximate 90% CI for the ratio of the test and 
reference product means was calculated. 
Intra-subject variability: 
 The intra-subject variability for each of the pharmacokinetic parameters reflect the 
residual variability after accounting for the difference between the subjects, periods, and 
treatments and was reported in terms of the overall co-efficient of variation (CV%), 
andseparately, from the ANOVA results using both untransformed and log-transformed 
data using the formula, 
Untransformed data = 100* (EMSE-1)1/2 
Where, MSE is mean square error 
Bioequivalence criteria:          
Based on the statistical results of 90% confidence intervals of the ratios of the 
means (Test/Reference) for Ln-transformed pharmacokinetic parameters Cmax, AUC0-t and 
AUC0-∞, conclusion was drawn to find whether the test product is bioequivalent to the 
reference product or not.  
Bioequivalence was concluded, if the Test to Reference (T/R) ratios and the 90% 
confidence interval for the ratios for the means fall within the acceptance range of  80% -
125% for the pharmacokinetic parameters, Cmax, AUC0-t  and AUC0-∞. 
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STUDY FLOW CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
                                                                                               
 
 
 
 
 
                                                                                                 
 
 
 
 
 
 
 
 
 
 
 
N - Number of subjects 
R - Reference Product 
T - Test Product 
PK - Pharmacokinetic 
 
 
 
 
Randomization 
Screening (within 28 days prior to study) 
Eligibility Criteria 
Subject Selection (N = 36) 
Period I 
 
               Treatment T (12)             Treatment R (12)                 Treatment R (12) 
 
Sample Analysis   
Washout 
(Minimum 07 Days) 
Crossover 
PK and Statistical Analysis 
(N≤36) 
Period II 
     
               Treatment R (12)   Treatment T (12)    Treatment R (12) 
  
Period III 
     
               Treatment R (12)        Treatment R (12)                  Treatment T (12) 
  
Washout 
(Minimum 07 Days) 
Crossover 
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RESULTS 
 This single oral dose comparative Bioavailability and Bioequivalence studywas 
undertaken to evaluate the bioequivalence and also, to monitor the adverse events of test 
product Tenofovir 245mg tablets in healthy subjects. 
 The study was designed to evaluate and compare the relative bioavailability of test 
and reference products of Tenofovir. 
 In this three period three way cross over study, 36 subjects who met the study 
inclusion and exclusion criteria were enrolled. 
 There was a washout period of 7 days between each ofthe three periods. The 
overall duration of the study was 19 days including the wash out period. Blood samples 
were collected at the predetermined time points to elicit the pharmacokinetic profiles of 
Tenofovir. 
 In this study, Test and Reference product containing Tenofovir were evaluated for 
the safety upon single dose administration to normal healthy adult male subjects under 
fed conditions.  
 Vital parameters measured at the scheduled time intervals were normal and within 
the acceptable range for all study subjects. 
 There was no death or serious adverse event reported in this study. 
 The Serum concentration level of Tenofovir was determined by a validated LC-
MS/MS method. 
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Pharmacokinetic analysis of test and reference products were evaluated based on 
measured Serum concentration of the drugs using Non compartmental Model 
ofWinNonlin® v 5.3. Primary pharmacokinetic parameters like Cmax, AUC0-t, AUC0-∞, and 
secondary pharmacokinetic parameters like Tmax,,  Kel, and T1/2 were calculated. 
The statistical analysis was performed using the SAS® statistical software (version: 9.2) 
Pharmacokinetic Parameters 
The pharmacokinetic parameters were estimated by using WinNonlin Software version 5 
TABLE-6: Mean values of various pharmacokinetic parameters for Tenofovir 
Parameters (Units) 
 
Tenofovir (Mean ± SD ) 
Test Reference 
Cmax(ng/ml) 396.477 ± 162.352 428.78 ± 161.184 
AUC0- t (ng.h/ml) 3233.891± 900.866 3348.358 ± 923.034 
AUC0-∞ (ng.h/ml) 3619.509 ± 987.754 3755.528 ± 989.920 
Tmax (hr) 1.941±1.134 1.856 ± 1.002 
Kel (hr-1) 0.041± 0.011 0.038± 0.011 
T1/2 (hr) 18.168± 4.610 19.922± 6.248 
AUC_%Extrap_obs 10.732  ±  4.250 11.074  ±  4.355 
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Tenofovir: 
Cmax--Peak or maximal serum concentration (Cmax): 
 Mean values (±SD) of Cmax for Tenofovir, treatment Test was 396.477 ± 
162.352ng/ml& for Reference was 428.78 ± 161.184ng/ml.  
The Test / Reference (T/R)  ratio of least square mean of log transformed Cmax 
was found to be 92.12%with 90% confidence interval LCL=83.71 %  and UCL= 101.38 
% therefore,90% CI lies with in the 80-125% window. 
AUC0-t--Area under the concentration-time curve: 
Mean values (±SD) of AUC0-t for Tenofovir, treatment T was 3233.891± 
900.866ng.h/ml& for Reference was 3348.358 ± 923.034ng.h/ml. 
The geometric mean ratio (AUCT/AUCR) was found to be 96.21 and the 
Confidence Interval for AUC0-t(Test versus Reference) of Tenofovir was found to be 
91.62% to 101.03% therefore,90% CI lies with in the 80-125% window. 
AUC0-∞--Area under the Concentration-Time curve: 
Mean values (±SD) of AUC0-∞ for Tenofovir, treatment T was 3619.509 ± 
987.754ng.h/ml& for Reference was 3755.528 ± 989.920ng.h/ml. 
The geometric mean ratio (AUCT/AUCR) was found to be 108.18 % and the 
Confidence Interval for AUC0-∞ (Test versus Reference) of Tenofovir was found to 
be105.63 % to 110.80 % therefore,90% CI lies with in the 80-125% window. 
Tmax:  
Mean values (±SD) of Tmax for Tenofovir, treatment Test was 1.941±1.134hr& for 
Reference 1.856 ± 1.002 hr. 
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Kel(hr-1): 
 Mean values (±SD) of Kel for Tenofovir, treatment Testwas 0.041± 0.011& for 
TreatmentReference was0.038± 0.011. 
 
T1/2(hr):  
Mean values (±SD) of T1/2 for Tenofovir, treatment Test was18.168± 4.610& for 
treatment Reference was19.922± 6.248. 
 
AUC_%Extrap_obs:  
Mean values (±SD) of AUC_%Extrap_obs for forTenofovir,treatment Test was 
10.732 ± 4.250& for treatment Reference was11.074 ± 4.355. 
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MAXIMUM SERUM CONCENTRATION (Cmax): 
 
TABLE 7- LATIN SQUARE DESIGN:  ANOVA TABLE 
PK Parameter Source DF 
Denominator 
df1 
F Value Pr > F 
Ln Cmax 
FORMULATION 1 32.6 2.10 0.1565 
SEQUENCE 2 31 1.15 0.3292 
PERIOD 2 64.4 3.19 0.0476 
 
Table-7 shows the Latin square design using ANOVA for Cmax. The period effect show 
statistically significant difference between the test and reference products. The sequence 
effect and formulation effect does not show any statistically significant difference 
between the test and reference products. 
Formulationeffects was Non-significant (at 5 % level of significance), when ANOVA 
was applied on Ln-transformed data for Cmax of Tenofovir. 
Sequenceeffects was Non-significant (at 10 % level of significance), when ANOVA was 
applied on Ln-transformed data for Cmax of Tenofovir. 
Periodeffects was significant (at 5 % level of significance), when ANOVA was applied 
on Ln-transformed data for Cmax of Tenofovir. 
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TABLE 8-Maximum Concentration (C max) 
 
Mean SD Min Max 
Test 396.477 162.352 158.44 743.75 
Reference 428.782 161.184 178.03 789.46 
Table 8 shows maximum, minimum, mean and SD values of Cmaxfor both Test and 
Reference products.  
 
Figure 5.1 
Figure 5.1 is the graphical representation of table-8. 
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AREA UNDER THE CURVE (AUC0-t): 
TABLE 9- LATIN SQUARE DESIGN:  ANOVA TABLE 
PK 
Parameter 
Source DF 
Denominat
or df1 
F Value Pr > F 
Ln AUC0-t 
FORMULATION 1 31.7 1.79 0.1903 
SEQUENCE 2 31 2.50 0.0985 
PERIOD 2 64.1 0.21 0.8142 
 
Table-9 shows the Latin square design using ANOVA for AUC0-t. The period effect, 
formulation effect show statistically significant difference between the test and reference 
products. Sequence effect does not show any statistically significant difference between 
the test and reference products. 
Formulation effects was non-significant (at 5 % level of significance), when ANOVA 
was applied on Ln-transformed data for AUC0-t of Tenofovir.  
Sequence effects was significant (at 10 % level of significance), when ANOVA was 
applied on Ln-transformed data for AUC0-t of Tenofovir.  
Period effects was non-Significant (at 5 % level of significance), when ANOVA was 
applied on Ln-transformed data for AUC0-t of Tenofovir.  
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TABLE 10-Maximum Concentration (AUC0-t) 
 
Mean SD Min Max 
Test 3233.891 900.866 1416.84 4877.86 
Reference 3348.358 923.034 1635.59 5003.7 
Table 10 shows maximum, minimum, mean and SD values of AUC0-t for both Test and 
Reference products. 
 
Figure 5.2 
Figure 5.2 is the graphical representation of table 10 
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AREA UNDER THE CURVE (AUC0-∞):  
TABLE 11- LATIN SQUARE DESIGN:  ANOVA TABLE 
PK 
Parameter 
Source DF 
Denominator 
df1 
F Value Pr > F 
Ln AUC0-∞ 
FORMULATION 1 32.6 1.97 
0.1893 
SEQUENCE 2 33 1.55 
0.1985 
PERIOD 2 61.7 3.23 
0.8142 
 
Table-11 shows the Latin square design using ANOVA for AUC0-∞. The period 
effect, formulation effect show statistically significant difference between the test and 
reference products. Sequence effect does not show any statistically significant difference 
between the test and reference products. 
Formulation effects was non- significant (at 5 % level of significance), when ANOVA 
was applied on Ln-transformed data for AUC0-t Tenofovir.  
Sequence effects was non-significant (at 10 % level of significance), when ANOVA was 
applied on Ln-transformed data for AUC0-t of Tenofovir. 
Period effects was non-significant (at 5 % level of significance), when ANOVA was 
applied on Ln-transformed data for AUC0-t of Tenofovir. 
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TABLE 12-TIME OF MAXIMUM MEASURED SERUM CONCENTRATION 
(AUC0-∞): 
 
Mean SD Min Max 
Test 3619.509 987.754 1563.73 6052.91 
Reference 3755.528 989.92 1865.99 6165.28 
 
The above Table-12 shows the maximum, minimum, mean and SD values of AUC0-∞for 
both Test and Reference products.  
Figure 5.3 
Figure 5.3 is the graphical representation of table 12. 
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TABLE 13-TIME OF MAXIMUM MEASURED SERUM CONCENTRATION 
 (T max): 
 
Mean SD Min Max 
Test 1.941 1.134 0.5 4 
Reference 1.856 1.002 0.5 4 
 
The above Table-13 shows the maximum, minimum, mean and SD values of T max   for 
both Test and Reference products.  
 
Figure 5.4 
  Figure 5.4 is the graphical representation of table 13. 
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TABLE 14-APPARENT FIRST ORDER ELIMINATION OR TERMINAL RATE 
CONSTANT (Kel)  
 
Mean SD Min Max 
Test 0.041 0.011 0.02 0.08 
Reference 0.038 0.011 0.02 0.07 
 
The above table- 14 shows the maximum, minimum, mean and SD values of Kel for both 
Test and Reference products.  
 
Figure 5.5 
Figure 5.5 is the graphical representation of table 14. 
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TABLE 15- HALF LIFE (t1/2): 
 
Mean SD Min Max 
Test 18.168 4.61 9.01 33.69 
Reference 19.922 6.248 9.49 42.36 
 
The above table 15-shows the maximum, minimum, mean and SD values of T ½ for both 
Test and Reference products.  
 
Figure 5.6 
Figure 5.6 is the graphical representation of table 15. 
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FIG-5.7: LINEAR PLOT OF MEAN SERUM
VS TIMEPOINTS 
 
The above Figure-5.7 shows the Means Serum
both the Test and Reference products (
 
 
 
 
 
TENOFOVIR CONCENTRATION 
Figure-5.7 
 Concentration Vs Various time points of 
Tenofovir). 
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FIG-5.8: SEMILOG PLOT OF MEAN SERUMTENOFOVIR CONCENTRATION 
VS TIME POINTS
 
 
Figure-5.8 
The above Figure-5.8 shows the Semilog plot of Mean Serum Concentration Vs. Various 
time points of both the Test and Reference products (Tenofovir). 
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TABLE-16 MEAN PLASMA CONCENTRATION: 
TIME (hours) TEST REFERENCE 
0.00 0.0000 0.0000 
0.25 66.0271 49.0092 
0.50 139.0682 140.5313 
0.67 174.4116 204.0747 
1.00 244.3947 249.6716 
1.25 260.0041 269.3234 
1.50 277.5960 295.3181 
1.75 270.8652 305.4892 
2.00 281.6349 289.8407 
2.25 268.3075 295.8611 
2.50 257.6074 286.2382 
2.75 257.4678 267.1530 
3.00 258.2784 252.8106 
4.00 217.5500 220.2209 
6.00 131.1337 133.9217 
8.00 104.4565 103.1272 
12.00 75.3821 74.1021 
16.00 58.0853 58.1338 
24.00 38.7909 39.9979 
36.00 25.0066 26.3980 
48.00 16.4316 17.4444 
72.00 3.0622 4.5153 
 
 
                                                                                                      Discussion 
 
INSTITUTE OF PHARMACOLOGY, MMC Page 70 
 
DISCUSSION 
Bioequivalence studies are fundamentally satisfied through single dose 
administration. The focus is on the rate and extent of absorption of the active ingredient. 
They are conducted in healthy normal subjects under fasting or fed conditions. Most 
comparative bioavailability studies are conducted to identify the quantitative with 
intravenous dose, modified release with conventional preparation and for a generic 
product, test and reference. 
 
Nowadays, bioequivalence studies are a pivotal part of registration dossiers. These 
studies measure the bioavailability of two or more formulations of the same active 
ingredient. The purpose of the study is to show the bioavailability of the formulations 
under investigation is equal. Based on the conclusion that the therapeutic qualities of 
these formulations are identical, these formulations can be interchangeable. 
 
In this study, Test and Reference product containing Tenofovir 245 mg were 
evaluated for the safety upon single dose administration to normal healthy adult male 
subjects under fed conditions. 
 
There was a washout period of 7 days between the three periods. The overall 
duration of the study was 19 days including the wash out period. Blood samples were 
collected at the predetermined time points to elicit the pharmacokinetic profiles of 
Tenofovir. 
 
Vital parameters measured at the scheduled time intervals were normal and within 
the acceptable range of all study subjects.. 
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This study was conducted with Tenofovir 245 mg (test) and Tenofovir245 mg(reference) 
to establish the drugs concentration versus time profile and the results of the 
pharmacokinetic analysis of Tenofovir of the test(T) product were compared with the 
reference(R) product.  
 
Analysis of variance for Ln-transformed pharmacokinetic parameters revealed that there 
was no significant variation between test and reference formulation for these three 
primary pharmacokinetic parameters Cmax and AUC0-t, &AUC0-∞. 
 
Cmax: 
 The statistical analysis did not show any significant difference between the 
groups. The geometric mean ratio was within the limits of reference confidence interval 
which was found to be 83.71 to 101.38 % (80 to 125%). This confirms the bioequivalence 
of the products. 
 
AUC 0-t: 
 The statistical analysis did not show any significant difference between the 
groups. The geometric mean ratio was within the limits of reference confidence interval 
that was found to be 91.62% to 101.31 % (80 to 125%). Therefore, bioequivalence can be 
concluded. 
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AUC 0-∞: 
 The statistical analysis did not show any significant difference between the 
groups. The geometric mean ratio was within the limits of reference confidence interval 
which was found to be 105.63 % to 110.80% (80 to 125%), which confirms 
bioequivalence. 
 
90% Confidence Interval: 
            The 90% confidence intervals of the T/R ratio of Ln- transformed Cmax, and AUC0-
t,AUC0-∞ were within the bioequivalence range of 80%-125%. 
 
Post study assessment of the haematological and biochemical parameters showed 
no significant changes on comparing with the respective baseline parameters. 
 
 The above parameters are similar which suggested that Tenofovir (Test) and   
Tenofovir (Reference) were bioequivalent. 
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CONCLUSION 
 
 From this study, we can conclude that the therapeutic quality of the formulation, 
test and reference Tenofovir 245 are identical. 
 The test Tenofovir is bioequivalent to reference Tenofovir. 
 Both the test and reference products have comparable safety profile. 
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Study title 
An open label, balanced, randomized, two treatment, three sequence, three period, single dose, cross over,  Semi-
replicate, oral bioequivalence pivotal study of  Tenofovir 245 mg Film Coated tablets .  and Tenofovir(viread®)245 
mg Film coated tablets of Gilead Sciences Intl Ltd.in  healthy, adult, human, male subjects under fed conditions. 
Protocol number AZ/P/04/13/15 Date of consent  
 
Name of the volunteer  Registration No.  
Date of birth  Phone number  
 
Person to be contacted in case of trial related injuries 
Name   
Relationship to the volunteer  Phone number   
Address 
 
 
 
Address to be contacted for compensation in case of claim in trial related injury or death 
Azidus Laboratories Ltd., 
23, School Road, 
Rathnamangalam, 
Vandalur,  
Chennai – 600048, India. 
Phone No. 91-44-27405244  
Fax: 91-44-27409734 
Mobile No: 9840915850 & 9444905295 
 
Dear Prospective Subject, 
You are invited to participate in a bioequivalence study, the title of which is given above. The purpose of this informed 
consent document is to clearly state the procedures of the study and to ensure that you enter the study only after knowing 
all relevant facts about it. An oral presentation of this document will be made after you go through this Informed 
Consent document. Only if you have understood all the salient aspects of the study procedures and decide to take part in 
this study, you will be asked to sign this Informed Consent Form in each page to confirm your voluntary participation in 
the study. A photocopy of the signed informed consent form will be given to you for your reference.   
Nature and purpose of this study 
You are being invited to participate in a bioequivalence study on a drug called Tenofovir. This study compares 
VIRTENIX (Tenofovir) 245 mg Film tablets of Pharmactive Ilac San. Ve Tic. A.Ş. Turkey and VIREAD® 245 mg Film 
coated tablets of Gilead Sciences Intl Ltd., Cambridge CB21 6GT, Verenigd Koninkrijk in 36 healthy, adult, human, 
male subjects under fed conditions whether these drugs achieve similar blood concentrations or not.  
VIRTENIX (Tenofovir) 245 mg Film tablets of Pharmactive Ilac San. Ve Tic. A.Ş. Turkey, is called the “Test 
Formulation” (T) and the formulation VIREAD® 245 mg Film coated tablets of Gilead Sciences Intl Ltd., Cambridge 
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CB21 6GT,  Verenigd Koninkrijk is called the “Reference Formulation” (R). You will receive the reference drug in two 
periods and the test drug in other period during your participation in this study.   
The drug(s) under investigation is not given to you to treat any disease nor is intended to improve your health status, but 
is given to you for the purpose of research.       
Drug information 
Tenofovir disoproxil is an antiretroviral or antiviral medicine which is used to treat HIV or HBV infection or both. 
Tenofovir is a nucleotide reverse transcriptase inhibitor, generally known as an NRTI and works by interfering with the 
normal working of enzymes (in HIV reverse transcriptase; in hepatitis B DNA polymerase) that are essential for the 
viruses to reproduce themselves. In HIV, Tenofovir should always be used combined with other medicines to treat HIV 
infection. 
Tenofovir may cause side effects of the following: 
Lactic acidosis (excess lactic acid in the blood). The following side effects may be signs of lactic acidosis: (Deep, rapid 
breathing, drowsiness, feeling sick (nausea), being sick (vomiting) and stomach pain). 
The other side effects which may occur with Tenofovir are as follows. 
Pain in the tummy (abdomen) caused by inflammation of the pancreas, inflammation of the kidney, passing a lot of urine 
and feeling thirsty, damage to kidney, tubule cells, changes to your urine and back pain caused by kidney problems, 
including kidney failure, softening of the bones (with bone pain and sometimes resulting in fractures), which may occur 
due to damage to kidney tubule cells, fatty liver, diarrhoea, being sick (vomiting), feeling sick (nausea), dizziness, rash, 
feeling weak, headache, stomach pain, feeling tired, feeling bloated, flatulence, breakdown of muscle, muscle pain or 
weakness. 
If you require more details about the study medication and other side effects, it will be provided to you.  
Total number of volunteers, number of visits and duration of study & stay 
This study will be carried out in 36 healthy, adult human male volunteers and it consists of 3 periods. After check-in, 
you need to stay in our clinic for at least 60 hrs, in each period. If you check-in today evening, study drug will be 
administered next day morning from the day of check in. After drug administration, you have to stay for at least 48.00 
hrs.  
There will be a wash out period of minimum 07 days between each period. Hence the total duration of study will be at 
least 19 days (from the day of check-in in period I to ambulatory sample of period III).    
Description of the Study Procedures 
Only healthy volunteers can participate in this study. To ensure that you are actually healthy, you have undergone a 
screening procedure and you are found to be eligible for the study. We obtained a similar consent from you for screening 
also. As a part of the screening, today we have tested your breath for whether you have consumed alcohol and your urine 
for whether you have consumed any drugs of abuse such as cocaine, amphetamine, tetra hydro cannabinoid, 
benzodiazepine, barbiturate and opioid. Similarly, when you come for check-in during the subsequent period, we will 
again test your urine and breath.  Alcohol breath test will be taken before ambulatory samples. 
Procedures after check-in 
Once you give consent to participate in the study, you will be subjected to check-in procedure, during which you need to 
keep all your belongings including cloths in the locker allotted to you. You have to wear the cloths that we provide.  
After subject check-in, dinner will be provided at a particular time between 08.30 pm and 09.30 pm. You can sleep in 
our clinical facility. You will be woken up around 05.00 am. You have to finish all your morning ablutions within    
06.00 am, after which you will be inserted an intravenous cannula. The study drug will be administered approximately at 
around 09.00 am. You need to stay at least 48 hrs after drug administration and you will be discharged from period I 
thereafter.  
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In this study, the concentration of the drug in your blood will be measured by giving the study medication under fed 
conditions. Hence you will be provided a high calorie, high fat breakfast on the day of study drug administration, 30 
minutes before dosing, which you need to eat the full quantity within 30 minutes. Standard food will be served at all 
other times (approximately at 04.00, 08.00, 12.00, 24.00, 28.00, 32.00 and 36.00 hrs post dose). During the entire stay in 
our facility, at scheduled time points, blood samples will be taken from you, vital parameters will be recorded and your 
well being will be assessed. The details of all these scheduled activities are given below. You will also be subjected to 
restrictions in the posture and activities which are dealt separately. 
All the activities carried out in period I will be carried out during period II and period III also. Timings described in this 
document may vary depending on the check in time & time of dosing and subjects will be updated about the changes. 
Study restrictions   
You will be restricted from smoking, consuming alcohol, taking carbonated drinks, coffee, tea and other caffeine 
containing drinks or food. You will have to eat only the food that we provide during the study. You will not be provided 
any food or juice containing grapefruit or other citrus fruits. You are also instructed not to consume the restricted food 
and drinks during the entire period of study including wash out period.  
Before breakfast, you will be put in at least 08 hrs of fasting. Water intake will be restricted one hour before drug 
administration and one hour after drug administration, except the 240 ± 02 ml of water given during the drug 
administration. Rest of the times water can be taken whenever you feel to take.  
During the entire duration of the study, you are restricted from taking any other medication including the over the 
counter (OTC) drugs. If you take any such medications, please inform the study personnel. Because, there are drugs that 
may interact with the study medication & result in adverse effects and it is for your safety for you to reveal the true 
information, if you have taken any other medication. 
After the ingestion of the study medication, you are required not to lie down for atleast 4 hrs. So, you have to be in the 
sitting position or you can be ambulatory. Throughout your stay in our clinical facility, you can enjoy the comfortable 
stay, but you are restricted from doing any strenuous activities.    
Blood sample collection 
00.00 hour (pre-dose), 00.25, 00.50, 00.67, 01.00, 01.25, 01.50, 01.75, 02.00, 02.25, 02.50, 02.75, 03.00, 04.00, 06.00, 
08.00, 12.00, 16.00, 24.00, 36.00, 48.00 and 72.00 hours post dose (Total of 22 samples - 4 ml each). First 21 samples 
will be collected as in-house samples and 72.00 hr sample will be collected as ambulatory sample. 
First 19 blood samples will be collected through an indwelling cannula placed in a forearm / arm vein and the last 03 
blood samples will be collected through direct venous puncture. After insertion of intravenous cannula and whenever 
blood is drawn from intravenous cannula, 0.5 ml of heparinised saline will be injected to prevent the cannula blockade. 
If there is difficulty in drawing blood from intravenous cannula due to blockade, blood will be drawn by direct venous 
puncture.    
The total volume of blood draw from each subject during the study will not exceed 308.5 ml. 
[22x4mlx3 = 264 ml] + [0.5 ml discarded for first 19 blood draws 19x0.5mlx3 = 28.5 ml] + [screening =10 ml] + [post 
study safety evaluation = 6 ml] = 308.5 ml. 
Vital parameter and well being assessment 
In each period, Pulse rate, blood pressure and body temperature will be recorded during check in, at before dosing, 00.00 
hr and at 02.00, 04.00, 06.00, 12.00, 24.00 hours post-dose, during check-out and ambulatory period. Your well being 
will also be assessed by asking “Are you feeling ok/good?” during the vital parameter assessment.  
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Risks or discomforts 
The important foreseeable risk that you may face during the study is the possibility of an adverse event or side-effect 
which may or may not be related to the drug.  
Apart from the adverse events, you may have to face the pain / discomfort of cannulation of the vein and repeated blood 
withdrawal and study restrictions as mentioned above.   
Unforeseeable risks 
Since this drug Tenofovir is in the market for quite some years and all aspects of its efficacy & safety are well studied, 
there are no unforeseeable risks associated with it. However, an allergic reaction is always a possibility associated with 
the usage of any drug and if any such reaction happens, we are well prepared to deal with it. 
Benefits to subjects/Society/Community  
Since you are a healthy volunteer and you do not suffer from any disease, you will not have any direct benefits by taking 
the study medication. But society in general will benefit from these studies because these studies help in introducing 
many formulations of the same drug in the market. Thus these studies increase competition and ensure availability of 
drugs at more cost effective prices. 
Alternative procedures or any other treatments 
No alternative procedures are available. If you don’t want to take the drug, then you can refuse to participate. 
Confidentiality of Records 
It may become necessary for us to seek details from you about your health and personal details.  Since this is mostly for 
your own safety, please do not hide any fact.  All your personal details and your identity will be kept strictly confidential 
at Azidus. The details will be revealed only when demanded by Governmental Regulatory Authorities, Independent 
Ethics Committee or sponsor’s inspectors / auditors. 
Subject Safety  
The study related documents such as the protocol, Informed Consent Document have been scrutinized by the 
Independent Ethics Committee (IEC) and have been approved.  
In case of study related injury or death, M/s. Azidus Laboratories Ltd., will provide complete medical care as well as 
compensation for the injury or death. Further in case of such injuries or deaths, the details of compensation provided will 
be intimated to Drug Controller General of India.  
If any adverse event happens to you due to your participation in this study, the necessary medical assistance will be 
provided at Azidus by the investigator or at a nearby hospital for which we ourselves will directly bear the cost. We will 
provide no monetary benefit for you other than providing the necessary medical care in case of any adverse events. 
Voluntary Nature of Participation  
Please remember that your participation in this study is entirely voluntary and this document is presented to you to help 
you in making an informed decision. If you have any doubts regarding the study, you can ask questions to any of our 
study staff and clarify them to your utmost satisfaction.  
Refusal to participate in this study will involve no penalty or loss of benefits, to which you might otherwise be entitled. 
Subject withdrawal   
You have the right to decide to participate or not to participate in the study. Even after giving consent, you have the right 
to withdraw from the study at any point of time without affecting your medical care.  
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Termination of subject participation 
At any point of time, your participation in the study may be terminated due to the following reasons, by the Principal 
Investigator even without your consent. 
1. You withdraw the consent. 
2. Development of intolerable adverse event due to study participation as determined by the investigator and / or 
yourself. 
3. Discovery that you entered the trial in violation of the protocol or occurrence of a significant protocol violation 
during the study. 
4. The investigator feels that in the best interest of your health, you have to be withdrawn from the trial.  
5. Any misbehavior or misconduct with any study personnel or with any other fellow subject, on disciplinary 
grounds or if you are noncooperative for the study conduct.  
Even when you are terminated from participating in the study, if you require any medical care it will be provided.  
Termination of the study 
The study at any point of time can be terminated even without the consent or knowledge of the subject. But the same will 
be intimated to all the subjects for information. The study can be terminated for the following reasons.  
1. The investigator and / or sponsor feel that the number and / or the severity of the adverse events justify the 
discontinuation of the study. 
2. Data not known before become available and raise concern about the safety of the study drug so that 
continuation would pose potential risks to the subjects. 
3. The Ethics Committee and / or regulatory authority may terminate the study, if continuation of study 
compromises subject safety.  
When the study is terminated prematurely, if the study subjects need any medical care it will be provided.  
Compensation to the subject 
As per our compensation policy, for the time and effort that you put in this study, you will be paid Rs. 4,195/- (Rupees 
Four thousand one hundred and ninety five only).        
Azidus Laboratories Ltd has an insurance policy to cover the medical expenses incurred during the management of 
adverse events that happen during the study. In case of study related injury or death, M/s. Azidus Laboratories Ltd., will 
provide complete medical care as well as compensation for the injury or death. Further in case of such injuries or deaths, 
the details of compensation provided will be intimated to Drug Controller General of India.  
You will be covered by contingency policy with insurance cover (The current policy is given by “United India Insurance 
Co. Ltd.” – Policy number 012600/46/12/39/00000162 effective from 07-OCT-2012; valid for a period of one year 
insured for the amount of Rs.80 Lakhs). A minimum compensation of Rs 5 Lakhs will be paid to you or your legal heir 
in case of study related injury or death respectively. The risks covered for death and physical disability arising out of 
such clinical trial and also hospitalization expenses arising out of illness consequent to such trials and Accidental 
damage cover.   
The address to be contacted incase of study related injury or death  
Azidus Laboratories Ltd., 23, School Road, Rathnamangalam, Vandalur, Chennai – 600048, India. Phone No. 91-44-
27405244, Fax: 91-44-27409734. 
Compensation for participation in the study will be paid to the volunteers proportionately at the end of the study.  
In case if your participation is terminated in the study due to medical reasons or if the study is terminated as per the 
sponsor’s or investigator’s decision, you will be paid the full compensation amount.  
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But if your participation in the study is terminated because of your withdrawal of consent or due to disciplinary reasons, 
the compensation will be proportionate to the stage of your participation in the study.   
Please note that the participation fee also includes your transportation to and from our facility. Hence no separate amount 
will be paid for transportation.   
New findings  
We have tried to provide you with the latest information regarding the drug and regarding comparative bioavailability 
studies. In case of any new information on the drug that might influence your decision to continue the study will be 
communicated to you and you may review your decision to continue your participation in the study based on such new 
information.  
Others 
In case of a serious adverse event, the physician has the authority to provide emergency medical care to ensure your well 
being without regard to the provisions of this document. 
When the adverse event is managed, at times, additional lab investigations including blood, urine, X ray, ECG and other 
necessary tests may be performed. By signing this form you also give consent to take any additional volume of blood 
required for further lab tests and for any other additional tests.  
Key study contacts 
For any questions about our location, how to get here, and what time to report, contact: Mr P Murugan, Manager- 
Clinical, Azidus Laboratories Ltd., Mobile No: 9840915850. 
If you have any questions about the study or the safety aspects or the study related injury and medical questions, contact: 
Dr S Gunasakaran, Principal Investigator, Azidus Laboratories Ltd., Mobile No: + 91 8056043873 
If you have any queries or clarifications about your rights in the study or about ethical aspects of the study, you can 
contact the IEC chairman at this address. 
Independent Ethics Committee, 132/1, Bharathi Colony, Anna nagar west, Chennai- 600040. Dr .P. Muthusamy, 
Member secretary, Mobile: 9444 233598. 
Declaration by the volunteer 
 Initial in the box 
i. I confirm that I have read and understood the information given above and have had 
the opportunity to ask questions and the study staff clarified them.         [                         ] 
ii. I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected.  
     [                         ] 
iii. I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
trial.  I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published.  
     [                         ] 
 
iv. I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s)     [                         ] 
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v. I understand that the volume of blood to be drawn from me will not exceed        
308.5 ml. However I understand that during the management of an adverse event, 
any additional amount of blood deemed to be necessary may be taken from me and I 
give consent for this and any other additional tests such as X ray, ECG and other 
tests performed during the management of adverse events 
    [                         ] 
vi. I agree to take part in the above study and I know that this study is carried out only 
for the purpose of research.     [                         ] 
 
 
Authorization 
I have read / been briefed on the above study and I voluntarily agree to participate in the project. I understand that 
participation in this study may not benefit me. Its general purpose, possible hazards, and inconveniences have been 
explained to my satisfaction. I hereby give my consent to participate in this study. 
 
Name of the Subject………………………………………………………… 
Address of the Subject.................................................................................... 
 
……………………………………………………………………………….. 
 
………………………………………………………………………………... 
 
Occupation of the Subject…………………………………………………… 
 
 
Qualification of the Subject…………………………………………………. 
 
 
Annual Income of the Subject........................................................................ 
Name of the Nominee(s)………………………………………………………… 
 
Address of the Nominee(s).................................................................................... 
 
……………………………………………………………………………….. 
 
………………………………………………………………………………...  
 (Copies of the Patient Information Sheet and duly filled Informed Consent Form shall be handed over to the 
subject) 
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Name of the subject Signature of subject Date 
   
 
Informed consent obtained by 
Name  Signature  Date 
   
 
 
I hereby declare that I have provided all the relevant information to the trial subject about the essential elements of 
clinical trial and the subject's rights to claim compensation in case of trial related injuries or death. I also informed the 
subject or shall also inform his/her legal heirs of their rights to contact M/s Azidus Laboratories Ltd, India and Ethics 
committee for the purpose of making claims in the case of trial related injury or death. 
 
In case of trial related injury, I will request the Ethics committee to review and make recommendations for the payment 
for medical treatment as well as compensation for the trial related injury or death of the subject. 
 
Name of the Investigator Signature  Date 
   
 
Subject’s Declaration 
I hereby declare that copy of duly filled Informed Consent Form was handed over to me. 
 
Name of the subject Signature of subject Date 
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ke<eiIuzIgtqe<! w{<{qg<< < < << < < << < < <jg?! wk<kje! Ljx! uVjgk<! kvOu{<Ml<! lx<Xl<! Nb<Ug<gizl<! lx<Xl<!< < < < < < < < < < << < < < < < < < < < << < < < < < < < < < <
kr<gqbqVg<gOu{<cb!gizl<!< < < << < < << < < <  
-f<k!Nb<uieK!47!!NOvig<gqblie!ohiqbuIgtqmk<kqz<?!ke<eiIuzIgtqml<?!4!gizr<gtqz<!Olx<ogit<th<hMl</!!
nElkqg<gh<hm<m!hqxG!fQr<gt<!wr<gt<!g<tqeqg<gqz<!Gjxf<khm<sl<!71!l{q!Ofvr<gt<!kr<gOu{<cbqVg<Gl</!!-e<X!
lijz!fQr<gt<!g<tqeqg<gqz<!nElkqg<gh<hm<miz<?!!fijtg<!gijzbqz<!dr<gTg<G!Nb<U!lVf<K!ntqg<gh<hMl</!
lVf<jk!dm<ogi{<m!hqxG?!fQr<gt<!Gjxf<khm<sl<!59!l{q!Ofvr<gt<!kr<gqbqVg<gOu{<Ml</!
Yu<ouiV! gizk<kqx<Gl<! -jmOb! Gjxf<khm<sl<! 18! fim<gt<! -jmoutq! -Vg<Gl</! nkeiz<! Nb<uqe<! olik<k!
gizlig! Gjxf<khm<sl<! 2:! fim<gt<! -Vg<Gl</! )Lkz<! gizk<kqz<! nElkqg<gh<hMl<! fitqz<! -Vf<K?! &e<xil<!
gizk<kqe< Nl<HOzm<mvq!Lcuqz<!outqObXl<!ujv*/!!
Nb<U!upqLjxgt<!Gxqk<k!uqtg<gl<< < < < << < < < << < < < <!
NOvig<gqblie!ke<eiIuzIgt<!lm<MOl!-f<k!Nb<uqz<!hr<Ogx<g!-bZl</!!fQr<gt<!NOvig<gqblig!-Vg<gqxQIgti!
we<hjk!dXkqosb<K! ogit<ukx<gig?! dr<gTg<G! sqz! hiqOsikjegt<! osb<bh<hm<M?! fQr<gt<! -f<k! Nb<Ug<G!
kGkqbieuI! we<X! g{<mxqbh<hm<Mt<tK/! ! -f<k! Lkx<gm<m! hiqOsikjegjt! osb<ukx<Gl<! dr<gtqml<! -Ok!
Ohie<x! yV! yh<Hkz<! ohxh<hm<mK/! ! -f<k! hiqOsikjegtqe<! yV! hGkqbig! fQr<gt<! lK! WKl<!
wMk<Kg<ogi{<Mt<tQIgti! we<hkx<gie! &s<Sg<gix<X! hiqOsikje! -e<X! osb<bh<hm<mK/! fQr<gt<! Ogijge<?!
Nl<hqomjle<?! omm<Ovijam<Ovi! Oge<ehqeib<M?! ohe<O^ijmo\jhe<?! hiIhqm<b,Ovm<! lx<Xl<! Yhqbib<M! Ohie<x!
Ohijk!lVf<Kgjt!wMk<Kg<! ogi{<Mt<tQIgti!we<hjk!nxqukx<gigUl<! osb<bh<hm<mK/!-Ok!Ohie<X!fQr<gt<!
lx<x!Nb<U!gizk<kqz<!nElkqg<gh<hMukx<gig!uVl<OhiKl<!sqXfQi<!hiqOsikjeBl<?!&s<Sg<gix<Xh<!hiqOsikjeBl<!
osb<bh<hMl</! oh{<gtig! -Vh<hqe<! gVUXkZg<gie! sqXfQi<! hvqOsikjeBl<! yu<ouiV! Nb<Ug<gizk<kqz<!
nElkqg<gh<hMl<!OhiKl<!osb<bh<hMl</!
Nb<uqx<gig!nElkqg<gh<hm<m!hqxG!Olx<ogit<th<hMl<!upqLjxgt<< < < < < < < < < << < < < < < < < < << < < < < < < < < <!
-f<k! Nb<uqz<! hr<Ogx<g! fQr<gt<! yh<Hkz<! ntqk<k! hqxG?! fQr<gt<! osg<! .! -e<! upqLjxgTg<G!
dm<hMk<kh<hMuQIgt</! ! nh<OhiK! fQr<gt<! dr<gTjmb! Njmgt<! dt<tqm<m! njek<Kh<! ohiVm<gjtBl<?!
dr<gTg<G! ntqg<gh<hm<m! zig<giqz<! juk<Kg<ogit<tOu{<Ml</! ! fir<gt<! ntqg<Gl<! djmgjt! fQr<gt<!
n{qf<Kogit<tOu{<Ml</!!!
g<tqeqg<gqz<!nElkqg<gh<hm<m!hqxG?!-vU!l{q!19/41!–!g<Gl<!1:/41!l{qg<Gl<!-jmbqz<?!yV!Gxqh<hqm<m!Ofvk<kqz<!
dr<gTg<G!-vU!d{U!ntqg<gh<hMl</!wr<gt<!g<tqeqg<gqOzOb!fQr<gt<!K~r<gzil</!!gijz!SliI!16/11!l{qg<G!
fQr<gt<! wPh<hquqmh<hMuQIgt</! ! gijz! SliI! 7/11! l{qg<Gt<! fQr<gt<!dr<gt<! gijzg<! gme<gt<!njek<jkBl<!
Lck<Kg<ogit<tOu{<Ml</!!nke<!hqxG!dr<gt<!dmzqz<!dt<t!yV!-vk<kg<!Gpibqz<?!hqti^<cg<!Gpib<!ye<X!
ohiVk<kh<hMl</! Okivibilig! gijz! 1:/11! l{q! Ohiz<?! Nb<U! lVf<K!dm<osZk<kh<hMl</! ! lVf<ktqk<k! hqxG?!
Gjxf<khm<sl<!59!l{q!Ofvr<gt<!fQr<gt<!g<tqeqg<gqz<!-Vg<gOu{<Ml</!!nke<!hqxG!Lkz<!Nb<U!gizk<kqzqVf<K!!
fQr<gt<!c^<siI\<!osb<bh<hMuQIgt!
-f<k!Nb<uqz<!d{U!dm<ogi{<m!$p<fqjzbqz<!Nb<U!lVf<jk!ntqk<K?!dr<gt<!vk<kk<kqz<!lVf<kqe<!nmIk<kq!
ntuqmh<hMl</! !weOu!Nb<U!lVf<K!ntqg<ghMl<! fitqz<!lVf<K!dm<ogit<ukx<G! 41!fqlqml<!Le<hig!nkqg!
ogiPh<H! lx<Xl<! gOziiq! ogi{<Mt<t! gijz! d{Ul<! upr<gh<hMl</! njk! kir<gt<! LpuKlig!!!!!!!!!!!!!
41!fqlqmk<kqx<Gt<!d{<{!Ou{<Ml<?!lx<x!hqx!Ofvr<gtqz<!ohiKuie!d{U!ntqg<gh<hMl<! )Okiviblig!15/11,!
19/11,! 23/11, 35/11, 39/11, 43/11! lx<Xl<! 47/11! l{q! Ofvr<gt<! lVf<K!dm<ogi{<mkqx<Gh<! hqxG*/! fQr<gt<! wr<gt<!
g<tqeqg<gqz<! -Vg<Gl<! gizk<kqz<?! Gxqh<hqm<m! Ofvr<gtqz<?! dr<gt<! dmzqzqVf<K! vk<k! likqiqgt<! wMg<gh<hMl?<!
dmzqe<! fick<! Kch<H?! dmz<! ouh<hfqjz! lx<Xl<! vk<k! nPk<kl<?! Suisqk<kqx<Gxqb! uqgqkl<?! Ohie<xju!
g{g<gqm<M?!hkqU!osb<bh<hMl<?!OlZl<!dr<gt<!dmz<fzLl<!lkqh<hqmh<hMl</!!Ofvh<hcbqzie!-f<k!osbz<hiMgt<!
njek<Kl<! gQOp! uquiqg<gh<hm<Mt<tK/! OlZl<!dr<gt<!dmz<! -Vg<Gl<! fqjz! lx<Xl<! osbz<hiMgTg<Gl<! sqz!
gm<Mh<hiMgt<!uqkqg<gh<hMl</!!-jugt<!Gxqk<K!keqbig!%xh<hm<Mt<tK/!!!
Lkz<!Nb<Ug<gizk<kqz<!Olx<ogit<th<hMl<!njek<K!osbz<gTl<!-v{<mil<!lx<Xl<!&e<xil<!Nb<Ug<!gizk<kqe<!
OhiKl<! Olx<ogit<th<hMl</! ! hr<Ogx<hitI! g<tqeqg<gqz<! nElkqg<gh<hMl<! Ofvl<! &! ! lVf<K! dm<ogit<Tl<!
Ofvk<jkh<! ohiXk<K?! -f<Ofvl<! liXhMl</! ! Ofv! lix<xr<gt<! Gxqk<k! kguz<gt<! dmEg<Gme<! hr<Ogx<hitVg<G!
okiquqg<gh<hMl </!
Nb<Ug<!gm<Mh<hiMgt<< < < < << < < < << < < < <!
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fQr<gt<!Hjgh<hqcg<gg<%miK/!!lK!nVf<k?!giIhOem<mm<!Gchier<gt<?!gi0hq?!C!lx<Xl<!hqx!gi0hqe<!nmr<gqb!
hier<gt<!nz<zK!d{Uh<ohiVm<gjt!wMk<Kg<ogit<t!nElkqg<glim<Omil</! !Nb<U!gizk<kqe<OhiK!fir<gt<!
ntqg<Gl<!d{ju!lm<MOl!fQr<gt<!dm<ogit<tOu{<Ml</!gqOvh<!0h<Vm<!!nz<zK!hqx!sqm<v^<!hpr<gt<!nmr<gqb!
wf<kuqk! d{Ul<?! hps<siXl<! wMk<Kg<ogit<tg<%miK/! kjmosb<bh<hm<m! d{U! lx<Xl<! Gchier<gt<! olik<k!
Nb<Ug<gizl<!LPjlg<Gl<?!-jmoutqg<gizl<!dm<hm?!d{<{ilz<!-Vg<GliX!fQr<gt<!nxqUXk<kh<hMgqxQi<gt</!!!
gijz! d{uqx<g<G! Le<hig?! Gjxf<khm<sl<! 19! l{q! Ofvl<! Le<hqVf<K! fQr<gt<! wf<k! d{Ul<!
dm<ogit<tg<%miK/! weOu?! Nb<uqx<G! Le<H! -vU!d{U! ntqg<gh<hm<m! hqxG?! fQjvk<! kuqv! OuX!d{Uh<!
ohiVm<gOti?! Gchier<gOti! dr<gTg<G! ntqg<gh<hmlim<miK/! lVf<jk! dm<osZk<Kl<OhiK! ntqg<gh<hMl<!
351±13!!lq/zq!fQjvk<!kuqv?!lVf<ktqh<hkx<G!yV!l{q!Ofvk<kqx<G!Le<hqVf<K?!lVf<ktqg<gh<hm<M!yV!l{q!Ofvl<!
hqe<H!ujv!GcfQVl<!nVf<kg<%miK/!hqx!slbr<gtqz<?!fQr<gt<!uqVh<hh<hMl<OhiK!GcfQjv!nVf<kzil</<!!!
Nb<Ug<! gizl<! LPuKl<?! fQr<gt<! lVf<Kg<! gjmbqz<! Ofiqjmbig! uir<Gl<! lVf<Kgt<! dm<hm?! OuX! wf<k!
lVf<KgjtBl<! wMk<Kg<ogit<tg<%miK/! yVOujt! fQr<gt<! WOkEl<! lVf<Kgjt! wMk<Kg<ogi{<miz<?!
-u<uqhvk<jk! fQr<gt<! Nb<U! okimIhie! fhiqml<! okiquqg<gOu{<Ml</! ! Woeeqz<?! -f<k! lVf<Kgt<?! Nb<U!
lVf<Kme<!OsIf<K!osbzix<xq?!dr<gt<!dmZg<G!kQr<gqje!Wx<hMk<kzil</!!weOu!fQr<gt<!OuX!WOkEl<!lVf<K!
wMk<Kg<ogi{<miz<?!dr<gt<!hiKgih<jh!Le<eqm<M?!d{<jljb!ljxg<gilz<!okiquqk<KuqmOu{<Ml</!!!
Nb<U!lVf<K!dm<osZk<kqb!hqxG?!Gjxf<khm<sl<! 15!l{q! Ofvl<!ujv!fQr<gt<! hMg<gg<%miK/!weOu!fQr<gt<!
nlIf<k! fqjzbqOzOb! -Vg<gOu{<Ml<! nz<zK! fmf<Kogi{<cVg<gzil</! ! wr<gt<! g<tqeqg<gqz<! fQr<gt<! fe<G?!
uskqbig! kr<gqg<ogit<tzil</! Neiz<! dmjz! uVk<Kl<hcbie! gMjlbie! osbz<gtqz<! =Mhm!
nElkqg<gh<hmlim<CIgt</    
vk<k!likqiq!Osgiqh<H< << << <  
00.00!l{q!)lVf<jk!dm<osZk<Kukx<G!Le<hig*?!lVf<K!dm<osZk<kqb!hqxG 00.25, 00.50, 00.67, 01.00, 01.25, 
01.50, 01.75, 02.00, 02.25, 02.50, 02.75, 03.00, 04.00, 06.00, 08.00, 12.00, 16.00, 24.00, 36.00, 48.00 lx<Xl<!72.00!
l{q! Ofvr<gtqz<! )olik<kl<! 33! Ljx! .! yu<ouiV! vk<k! likqiqBl<! 15! lq/zq/! wMg<gh<hMl*</! Lkz<! 32! vk<k!
likqvqgTl<!g<tqeqg<gqz< nElkqg<gh<hm<M!-Vg<Gl<OhiK!wMg<gh<hMhju/!83/11!l{q!vk<k!likqiq!Nl<HOzm<mvqbqz<!
wMg<gh<hMl/<!!
Lkz<! 2:! vk<k! likqiqgt<! Lpr<jg! / jgbqz<! dt<t! -vk<k! Gpib<g<Gt<! osVgh<hm<m! hqti^<cg<! Gpib<gt<!
&zlig! wMg<gh<hMl<?! gjmsqbig! wMg<gh<hMl<! &e<X! vk<k! likqiqgt<! Ofiqjmbig! -vk<kg<Gpibqz<! Kjtbqm<M!
wMg<gh<hMl</! !nu<uiX! vk<kl<! wMg<gh<hMl<OhiK?! osVG!Gpibqz<!njmh<H! WKl<! wx<hmilz<!-Vh<hkx<gig! 1/6!
lqzq! oahiiqje^<M! sjze<! dm<osZk<kh<hMl</! osVG! Gpibqz<! njmh<H! Wx<hm<M?! nkeiz<! -vk<klikqiq!
wMh<hkqz<!okif<kvU!Wx<hm<miz<?!-vk<kl<!Ofiqjmbig!-vk<kg<Gpibqz<!Kjtbqm<M!wMg<gh<hMl</!!
fQr<gt<!-f<k!Nb<uqz<!hr<Ogx<hke<!&zlig!wMg<gh<hMl<!vk<kk<kqe<!olik<k!ntU!419/6!lq/zq/!–!Jk<!ki{<miK!
[22x 4 lq/zq x3 = 264 lq/zq]+[0.5 lq/zq wMk<Kg<ogit<th<hmik!2:!vk<k likqiqgt<  19 x 0.5lq/zq x3 = 28.5  lq/zq] +!
[Nb<uqz<! hr<Ogx<hkx<G!Le<! osb<bh<hm<m!dmz<! hiqOsikjeg<gig! 21! lq/zq] + <! [Nb<uqx<G! hqf<jkb! hiKgih<H!
Osikjeg<gig!7!lq/zq] != 308.5 lq/zq/     
Lg<gqb!dmz<fzg<!giv{qgt<!lx<Xl<!dmz<fzl<!lkqh<hQM< < < < < < < < < Q< < < < < < < < < Q< < < < < < < < < Q  
fQr<gt<! g<tqeqg<gqz<! nElkqg<gh<hMl<! OhiKl<?! Nb<uqe<OhiK! lVf<ktqh<hkx<G! Le<H,! Nb<U! Lcf<K!
osz<Zl<OhiKl<<?! fick<Kch<H?! vk<k! nPk<kl<?! dmz<! ouh<hfqjz! Ohie<xju! lkqh<hqmh<hMl</! 11/11! l{q!
Ofvk<kqZl<?! lVf<ktqk<k! hqxG! 13/11,! 15/11,! 17/11,! 23/11, 35/11!  !NuK! l{q! Ofvk<kqZl<! fick<Kch<Hl<?! vk<k!
nPk<kLl<! lx<Xl<!dmz<! ouh<hfqjz! g{g<gqmh<hMl</! OlZl<! -f<kh<! hiqOsikjegtqe<OhiK?! ”fQr<gt<! fe<xig!
dt<tQIgti@”!we<X!Ogt<uqgt<!Ogm<hke<!&zlig!dr<gt<!dmz<fzl<!lkqh<hqmh<hMl</!
Nhk<Kgt<!nz<zK!sqvlr<gt<< < < < << < < < << < < < <!
-f<k!Nb<uqz<!hr<Ogx<Gl<OhiK?!wkqIOfig<Gl<!uib<h<Hjmb!Nhk<K?!lVf<kqe<!giv{ligOui!nz<zK!lVf<Kme<!
okimIhqe<xqObi!Wx<hmg<%cb!kQr<gie!hqe<!uqjtUgt<!nz<zK!hg<g!uqjtUgOt!NGl</!!
-f<k!kQr<gie!uqjtUgjtk<!kuqv?!lQ{<Ml<?!lQ{<Ml<!dr<gt<!dmzqzqVf<K!vk<kl<!wMg<Gl<OhiK!uzq!Wx<hmzil</!!
OlZl<!OlOz!%xh<hm<Mt<t!gm<Mh<hiMgTl<!dr<gTg<G!sqvlk<jk!Wx<hMk<kzil</   
wkqIhivik!Nhk<Kgt<< << << <!
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-f<k<! omOei0ohiuqv<! lVf<K?! sf<jkbqz<! sqz!N{<Mgtig!Hpr<gq!uVukiz<?!-l<lVf<kqe<!uqjtUgt<! lx<Xl<!
hiKgih<H! Gxqk<K! fe<G!Nb<U! osb<bh<hm<Mt<tK/! ! -OkiM! okimIHjmb! wkqIhivik!Nhk<Kgt<! WKlqz<jz/!!
-Vh<hqEl<! wf<k! lVf<Kgt<!dm<ogi{<miZl<! Wx<hMl<! sqz!nzI\qgt<! -keiz<! Wx<hmzil</! !nu<uiX! Wx<hMl<!
nzI\qjbg<!jgbit!fir<gt<!kbivig!dt<Otil</!!
hr<Ogx<hitI!< << << < /!s&gk<kqx<G!Wx<hMl<!hbe<gt<< < < < < << < < < < << < < < < <!
fQr<gt<! yV! NOvig<gqblie! ke<eiIuzvig! -Vh<hkiZl<?! dr<gTg<G! Ofib<gt<! WKl<! -z<zikkiZl<?! -f<k!
Nb<U! lVf<jk! wMk<Kg<ogit<ukiz<! Ofiqjmbig!dr<gTg<G! wf<k! hbEl<! Wx<hmiK/! ! -Vh<hqEl<! ohiKuig!
s&gk<kqx<G! -keiz<! hbe<! Wx<hMl</! Woeeqz<! -f<k! Nb<Ugt<?! -Ok! lVf<kqe<! hz<OuX! 0hiILOz]e<gjt!
sf<jkbqz<! nxqLgh<hMk<k! dkuqgvlig! -Vg<Gl</! ! -ke<! &zlig! Ohim<c! nkqgiqk<K?! Gjxf<k! uqjzbqz<?!
-l<lVf<Kgt<!wh<OhiKl<!gqjmh<hK!dXkq!osb<bh<hMl</ 
lix<X!upqLjxgt<!nz<zK!OuX!hqx!sqgqs<jsgt<< < < < << < < < << < < < < 
lix<X! upqLjxgt<! WKlqz<jz/! ! fQr<gt<! -l<lVf<jk! wMk<Kg<ogit<t! uqVl<hiuqm<miz<?! fQr<gt<! hr<Ogx<hkx<G!
lXh<H!okiquqg<gzil</ 
Nu{r<gtqe<!vgsqbg<gih<H< < < << < < << < < <  
dr<gjtg<! Gxqk<Kl<?!dr<gt<!dmz<fzl<! Gxqk<Kl<! sqz! keqh<hm<m! uqhvr<gjt! ohxOu{<cbK!nusqbliGl</!!
ohVl<hiZl<!-K!dr<gt<!hiKgih<hqx<gigOu!Ogm<gh<hMukiz<?!kbUosb<K!wf<k!d{<jljbBl<!ljxg<gikQIgt</!
dr<gjt!Gxqk<k!keqh<hm<m!njmbitl<!lx<Xl<!uquvr<gt<!vgsqblig!n^qm^qz<!hiKgig<gh<hMl</!-u<uqvr<gt<!
nvS! yPr<GLjx! njlh<Hgt<?! Sblig! -br<Gl<! nxofxqg<! GPg<gt<! nz<zK! Nb<ju! Olx<ogit<Tl<!
njlh<hqe<!Nb<uitIgt<!/!k{qg<jgbitIgTg<G!lm<MOl?!nuIgt<!OgiVl<OhiK!ntqg<gh<hMl</ 
hr<Ogx<<< <hitIgtqe<!hiKgih<H< < << < << < <   
HOvim<Omigiz<?! kguz<! nxqf<Kogi{<mjlg<gie! yh<Hkz<! Nu{l<! Ohie<x! Nb<Uk<! okimIhie! Nu{r<gt<?!
Sblig!-br<Gl<!nxofxqg<!GPuqeviz<!)IEC*!hiqsQzqg<gh<hm<M?!nr<gQgiqg<gh<hm<Mt<tK/!
Nb<U! okimv<hie! dmz<! hikqh<H! nz<zK -xh<H! Wx<hm<miz<?! nkx<gie! LP! lVk<Ku! hvilvqh<H! lx<Xl<!
=m<Mk<okijg!n^qm^<!ozhivm<vQ^ <!fqXuek<kiz<!ntqg<gh<hMl</!Nb<U!okimv<hie!gibr<gt< nz<zK!kQuqvlie!
hg<guqjtUgt<<!<< -xh<H Wx<hm<miz<! -ph<hQM! uquvk<jk! -f<kqb! lVf<K! gm<Mh<him<M! o\evz<! Njebk<kqml<!
okvquqg<gh<hMl/<!
fQr<gt<! -f<k! Nb<uqz<! hr<Ogx<hke<! giv{lig! WOkEl<! kQr<G! uqjtuqg<Gl<! hqe<! uqjtUgt<! Wx<hm<miz<?!
n^qm^qe<! Nb<uitviOzObi! nz<zK! nVgqZt<t! lVk<KuljebqOzi?! Okjubie! lVk<Ku! sqgqs<jsgt<?!
wr<gt<! oszuqOzOb! ntqg<gh<hMl</! ! WOkEl<! kQr<gie! hqe<! uqjtUgt<! Wx<hm<miz<?! Okjubie! lVk<Ku!
hviliqh<jhk<!kuqv?!OuX!WKl<!h{l<!kvh<hmlim<miK/!
Sb!uqVh<hk<kqe<!OhiqOzOb!Nb<uqz<!hr<Ogx<H< < < < < < << < < < < < << < < < < < <  
Lx<xqZl<! dr<gt<! Sb! uqVh<hk<kqe<! OhiqOzOb?! fQr<gt<! -f<k! Nb<uqz<! hr<Ogx<gqxQIgt<! we<hjk! kbUosb<K!
fqjeuqz<! ogit<tUl<?! fQr<gt<! Nb<uqz<! hr<Ogx<hK! Gxqk<K! yV! LcUg<G! uVukx<gigOu! -f<k! Nu{l<!
dr<gTg<G! upr<gh<hm<Mt<tK/! ! -f<k! Nb<U! Gxqk<K?! dr<gTg<G! WOkEl<! sf<Okgr<gt<! -Vf<kiz<?! wr<gt<!
Nb<Uh<!h{qbitIgt<?!biiqmLl<!fQr<gt<!Ogt<uqgt<!Ogm<M?!fQr<gt<!kqVh<kq!njmBl<!ujgbqz<!uqtg<gr<gjth<!
ohxUl</!
fQr<gt<! -f<k! Nb<uqz<! hr<Ogx<g! lXk<kiz<?! dr<gTg<G! nhvikl<! WKl<! uqkqg<gh<hmlim<miK! nz<zK! hqx!
upqgtqz<?!dr<gTg<G!gqjmg<gg<%cb!hbe<gt<!WKl<!lXg<gh<hmiK/!
hr<Ogx<hitI!uqzgqg<ogit<Tkz<< < < < << < < < << < < < <!
-f<k!Nb<uqz<! hr<Ogx<gzili!nz<zK!Ou{<mili!we<X!LcouMg<Gl<!diqjl!dr<gTg<G!dt<tK/!!fQr<gt<!
yh<Hkz<! ntqk<k! hqxGl<?! dr<gt<! lVk<Ku! hviliqh<H! hikqg<gh<hmilz<?! Nb<uqe<! wf<k! yV! slbk<kqZl<!
Nb<uqzqVf<K!uqzgqg<ogit<tzil</!
hr<Ogx<hitI!Nb<uqz<!hr<Ogx<hK!LcUg<G!uVkz<< < < < < < < << < < < < < < << < < < < < < < 
dr<gt<! yh<Hkz<! -z<zilOzOb?! fQr<gt<! Nb<uqz<! hr<Ogx<hjk! wf<k! yV! slbk<kqZl<! Lke<jl! Nb<uitviz<!
gQp<g<g{<m!giv{r<gTg<gig!fQg<gh<hmzil</ 
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2/ fQr<gt<!yh<Hkjz!uqzg<gqg<ogi{<miz</!
3/ Nb<uqz<!hr<Ogx<hke<!giv{lig?!kir<gLcbik!kQb!uqjtUgt<!Wx<hm<Mt<tkig?!fQr<gOti!/ Nb<uitOvi!
LcU!osb<kiz<!
4/ %xh<hm<Mt<t! uqkqLjxgjth<! hqe<hx<xilz<! Nb<uqz<! hr<Ogx<xqVh<hK! g{<mxqbh<hm<miOzi! nz<zK!
Nb<uqe<OhiK!WOkEl<!uqkqLjxgt<!lQxh<hm<miOzi!
5/ dr<gt<! dmz<fzje! hiKgih<hkx<gig?! fQr<gt<! -f<k! Nb<uqzqVf<K! gm<mibl<! uqzgOu{<Ml<! we<X!
Nb<uitI!gVkqeiz<!
6/ Nb<Uh<! h{qbitIgTmOei! nz<zK! sg! hr<Ogx<hitIgTmOei! WOkEl<! yV! ujgbqz<! kuxig!
fmf<Kogi{<miOzi!nz<zK!Nb<U!fjmLjxg<G!yk<Kjpg<gilz<!-Vf<kiOzi/!
fQr<gt<! Nb<uqzqVf<K! uqzg<gh<hm<miZl<?! dr<gTg<G! WOkEl<! lVk<Ku! sqgqs<jsgt<! Okjuh<hm<miz<!
ntqg<gh<hMl</  
Nb<uqje!vk<K!osb<kz<< < < << < < << < < <!
hr<Ogx<hitiqe<!yh<Hkzqe<xqObi!nz<zK!nuVg<G!Le<%m<c!okiquqg<gilOzi?!wf<k!yV!slbk<kqZl<!Nb<U!vk<K!
osb<bh<hmzil</! ! -Vh<hqEl<?! -k<kguz<! njeuVg<Gl<! hqe<H! okiquqg<gh<hMl</! ! gQp<g<g{<m! giv{r<gTg<gig!
Nb<U!vk<K!osb<bh<hmzil</!!!
2/ Nb<uitI! lx<Xl<! /! nz<zK! Nb<U! Olx<ogit<Tl<! fqXuel<! Nb<uqz<! gi{h<hMl<! kQb! uqjtUgtqe<!
w{<{qg<jg! giv{k<kiOzi! lx<Xl<! /! nz<zK! kQb! uqjtUgtqe<! gMjl! giv{ligOui! Nb<ju! vk<K!
osb<bOu{<Ml<!we<X!LcU!osb<kiz</!
3/ Nb<uqx<G! Le<H! gqjmg<gik! kguz<?! -h<OhiK! gqjmg<gh<ohx<X?! dr<gt<! hiKgih<H! Gxqk<K! WOkEl<!
sf<Okgr<gt<!Okie<xq?!okimIf<K!Nb<uqz<!=MhMukiz<?!Nhk<Kgt<!Wx<hMl<!uib<h<Ht<tkig!Okie<xqeiz</!
4/ Nb<uqje! okimIf<K! fmk<KuK?! hr<Ogx<hitiqe<! hiKgih<Hg<G!Nhk<K! uqjtuqg<Gl<! we<X!nxofxqg<! GP!
lx<Xl<!/!nz<zK!yPr<GLjx!njlh<H!Nb<ju!vk<K!osb<kiz<!!
Nb<U! LcUg<G! uvilOz! vk<K! osb<bh<hm<miZl<?! Nb<uqz<! hr<Ogx<xuIgTg<G! WOkEl<! lVk<Ku! sqgqs<js!
Okjuh<hm<miz<?!okimIf<K!ntqg<gh<hMl</  
hr<Ogx<hitVg<gie!=m<Mk<okijg< < < < << < < < << < < < <   
wr<gt<! =m<Mk<okijg! ogit<jgbqe<hc?! -f<k! Nb<uqz<! hr<Ogx<hkx<gig! fQr<gt<! oszupqg<Gl<! Ofvl<! lx<Xl<!
Lbx<sqgTg<gig!dr<gTg<G!'/!4,195/- !)'hib<!!fie<gibqvk<K!Fix<X!okie<Ex<X!Jf<K!lm<Ml<<*!upr<gh<hMl</!!
-f<k!lVk<Ku!Nb<uqz<?!hg<g!uqjtUgtiz<!Wx<hMl<!lVk<Ku!sqgqs<jsg<gie!gih<HXkq!hizqsqjbBl<!n^qm <^!
ohx<Xt<tK/!Nb<U!okimv<!dmz<!hikqh<H!nz<zK!-xh<H!Wx<hm<miz<?!nkx<gie!LP!lVk<Ku!hvilvqh<H!lx<Xl<!
=m<Mk<okijg!n^qm^<!ozhivm<vQ^ <<!fqXuek<kiz<!ntqg<gh<hMl</!Nb<U!okimv<hie!gibr<gt< nz<zK!kQuqvlie!
hg<guqjtUgt<<!<< -xh<H Wx<hm<miz<! -ph<hQM! uquvk<jk! -f<kqb! lVf<K! gm<Mh<him<M! o\evz<! Njebk<kqml<! :1!
fim<gTg<Gt<!okvquqg<gh<hMl/<!
-kqz<!dr<gTg<G!wkqv<!hivik!oszUg<gig!gih<HXkq!hizqsqBl<!nmr<Gl<)kx<Ohijkb!hizqsq!Bjeomm<!-f<kqbi!
-e<$ve<^ <! Ogi!zqlqomm<!upr<gqBt<tK/!hizqsq!w{<!123711/57/23/4:/11111273!osz<ZhcbiGl<!gizl<!!18.ng<.
3123!Lkz<! yV!uVml<! ujv!-f<k! gih<hQM! '/91 zm<sl<*! Gjxf<khm<s -ph<hQM!LjxOb  '! 6!zm<sl<!Nb<U!
okimv<hie!gibl<!nz<zK!-xh<H!uq]bk<kqz<!dr<gt<!sm<m!uivqSgTg<G!upr<gh<hMl</ lVk<Ku!Osikje!&zl<!
Wx<hmik!kx<osbzie!dmz<!Del<!nz<zK!-xh<H!lx<Xl<!Ofib<g<gie!lVk<KuoszUgt< nmr<Gl/<  
Nb<U!okimv<hie!hikqh<Hgt<!nz<zK!-xh<H!Wx<hm<miz<!-ph<hQM!ohXukx<G!okimv<H!ogit<t!Ou{<cb!Lguiq 
n^qm^<!ozhivm<iQ^ <!zqlqomm<?!34?!ht<tq!sijz-!vk<kqelr<gtl-<!u{<mZiv<.!!ose<je!–!600048!-f<kqbi.  
Ohie<;!91-4427405244!/;!Ohg<^ <;!91- 44- 27409734/!
Nb<uqz<! gzf<K! ogit<ukx<gie! =m<Mk<okijgbeK! yu<ouiV! Nb<Ug<! gizk<kqe<! LcuqZl<! Nb<uqz<! gzf<K!
ogi{<m!ntU!ujvg<Gl<!upr<gh<hMl</!!!!!!!!!!!!!!!!!!!
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lVk<Ku!giv{r<gtiz<!Nb<uqzqVf<K!fQr<gt<!uqzg<gh<hm<miZl<?!nz<zK!Nb<U!Olx<ogit<Tl<!njlh<H!nz<zK!
Nb<uitiqe<!Lcuqe<!hc!Nb<U!vk<K!osb<bh<hm<miZl<?!LP!=m<Mk<okijgBl<!dr<gTg<G!ntqg<gh<hMl</!
Neiz<!fQr<gOt!yh<Hkjz!uqzg<gqg<ogit<ukiOzi!nz<zK!yPr<G!fmucg<jg!giv{lig!fQr<gt<!Nb<uqzqVf<K!
uqzg<gh<hm<miOzi?!fQr<gt<!Nb<uqz<!hr<Ogx<x!ntuqx<Ogx<h!=m<Mk<okijg!upr<gh<hMl</!!
-f<k! hr<Ogx<hitI! gm<m{k<kqz<! fQr<gt<! Nb<uqx<G! uf<K! osz<ukx<gie! Ohig<Guvk<K! oszUgTl<! nmr<Gl</!!
weOu!Ohig<Guvk<K!oszuqx<gig?!keqbig!okijgObKl<!ntqg<gh<hmlim<miK/!!
Hkqb!kguz<gt<< << << <!
lVf<K! Gxqk<Kl<! lx<Xl<! yh<hqMl<! hObinoub<zhqtqm<c! Nb<Ugt<! Gxqk<Kl<?! slQhgizl<! ujvbqzie! njek<K!
kguz<gjtBl<! upr<g! fir<gt<! Lbx<sqk<Kt<Otil</! ! -l<lVf<K! Gxqk<K?! -f<k! Nb<uqz<! fQr<gt<! hr<Ogx<Gl<!
Lcju! lXhiqsQzje! osb<bk<! K~{<Ml<! Hkqb! kguz<gt<! WOkEl<! gqjmg<gh<ohx<xiz<?! nK! dmecbig!
dr<gTg<G!okiquqg<gh<hMl</!!-f<k!Hkqb!kgujz!nch<hjmbigg<!ogi{<M?!fQr<gt<!-f<k!Nb<uqz<!okimIf<K!
hr<Ogx<hK!Gxqk<K!lXhiqsQzje!osb<bzil</<!
hqx!kguz<gt<< << << <!
WOkEl<!gMjlbie!uqjtUgt<!Wx<hm<miz<?!-f<k!Nu{k<kqz<!dt<t!hqiqUgjt!gVk<kqz<!ogit<tiK?!dr<gt<!
dmz<fzje!hiKgih<hkx<Ogx<x!nusvgiz!lVk<Ku!sqgqs<js!ntqg<Gl<!nkqgivl<!lVk<KuVg<G!dt<tK/!kQb!
uqjtUgt<! siqbig! jgbith<hm<miZl<?! sqz! slbr<gtqz<! vk<kl<?! sqXfQI?! wg<^<Ov?! =sq\qlx<Xl<! hqx! nusqb!
hiqOsikjegt<! osb<bOu{<cbqVg<gzil</! ! -f<k! hcuk<kqz<! fQr<gt<! jgobih<hlqMuke<! &zlig?! %Mkz<!
hiqOsikjegTg<G!Okjuh<hMl<!%Mkz<!vk<kk<jk!wMh<hkx<Gl<!fQr<gt<!yh<Hkz<!ntqg<gqxQIgt</!
Lg<gqb!Nb<< << << <Uk<!okimIhitIgt<< << << <!
wr<gt<! -Vh<hqml<?! nr<G! wu<uiX! uvOu{<Ml<?! wf<k! Ofvk<kqz<! uvOu{<Ml<! we<hK! Gxqk<k! uqhvr<gt<! hx<xq!
WOkEl<!Ogt<uqgt<!Ogm<g!uqVl<hqeiz<!okimIHogit<g;!
kqV/!h/LVge<?!n^qm^<!ozhivm<iQ^<!zqlqomm<?!olijhz<!w{<;!9840915850  
Nb<U!nz<zK!hiKgih<H!nl<sr<gt<!nz<zK!Nb<U!okimIhie!gibr<gt<!Gxqk<K!WOkEl<!Ogt<uqgt<! Ogm<g!
uqVl<hqeiOzi!nz<zK!lVk<Kug<!Ogt<uqgt<!Ogm<g!uqVl<hqeiOzi!okimIHogit<g; 
mig<mI!NI/!G{sigve<?!Lke<jl!Nb<uitI?!n^qm^<!ozhivm<iQ^<!zqlqomm<, olijhz<!w{<;!+ 91 8056043873 
-f<k!Nb<uqz<!dr<gTg<Gt<t!diqjlgt<!Gxqk<K!WOkEl<!uqsivj{gt<!nz<zK!oktqU!ohx!uqVl<hqeiOzi!
nz<zK!Nb<uqe<!nxofxq!nl<sr<gt<!Gxqk<K!WOkEl<!Ogm<g!uqVl<hqeiOzi!IEC!–!bqe<!kjzujv!gQp<g<g{<m!
Lguiqbqz<!okimIHogit<tzil</!
Sblig!-br<Gl<!ofxqLjx!GP?!132/1?!hivkq!gizeq?!!n{<{i!fgv<!Olx<G?!!ose<je–!600 040/!mig<mI!hq!
Lk<Ksilq!oll<hv<!osgvm<mvq?!olijhz<!w{<;!9444 233598/!!
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!
/!
ke<eiIuziqe<!dXkqolipq< << << <  
 
gm<mk<kqz<!-eq]qbz<!
OhimUl< 
i. OlOz!%xh<hm<Mt<t!kguz<gjt!fie<!hck<K!Hiqf<Kogi{<Ome<!we<X!dXkq!
ntqg<gqe<Oxe</!!OlZl<!weg<G!Ogt<uqgt<!Ogm<g!uib<h<H!ntqg<gh<hm<mK!
we<Xl<?!Nb<Uh<!h{qbitIgt<!oktquie!uqtg<gr<gjt!ntqk<kiIgt<!we<Xl<!
dXkq!ntqg<gqe<Oxe</!!!!
     [                         ] 
ii. weK! Sb! uqVh<hk<kqe<! OhiqOzOb! fie<! -f<k! Nb<uqz<! hr<Ogx<gqOxe<!
we<hjkBl<?! giv{l<! WKl<! okiquqg<gilz<?! weK! lVk<Ku! hviliqh<Ohi?!
sm<mh<hcbie!diqjlgOti!hikqg<gh<hmilz<!wf<k!yV!slbk<kqZl<!Nb<uqzqVf<K!
uqzgqg<ogit<ukx<gie!diqjl!weg<Gt<tK!we<hjkBl<!nxqf<Kogi{<Mt<Ote</!!
     [                         ] 
iii. fie<! gzf<K! ogit<Tl<! kx<Ohijkb! Nb<Uk<! okimIhie! weK! dmz<fzl<!
Gxqk<k! hkqUgjtBl<?! fie<! Nb<uqzqVf<K! uqzgqg<ogi{<m! hqxGl<! weK!
dmz<fzl<! Gxqk<k! hkqUgjtBl<! weK!nElkqbqe<xq! -f<k! lVk<Ku!Nb<ju!
Olx<ogi{<Mt<t! fqXuel<?! -f<fqXuek<kqe<! siIhig! h{qbix<XOuiI?! nxofxqg<!
GPuqeI! lx<Xl<! ypr<GLjx! njlh<hqeI! NgqObiI! gi{<hI! we<hjk! fie<!
nxqf<Kogi{<Mt<Ote</! ! -kx<G! fie<! yh<Hg<ogit<gqOxe</! ! -Vh<hqEl<! &e<xil<!
fhIgTg<G!okiquqg<gh<hMl<!nz<zK!outqbqmh<hMl<!wf<k!yV!kguzqZl<?!weK!
njmbitl<!outqh<hMk<kh<hmiK!we<hjkBl<!nxqf<Kogi{<Mt<Ote</!!
      
     [                         ] 
iv. -f<k! Nb<U! &zlig! gqjmg<Gl<! kguz<gt<! nz<zK! LcUgjt?! nxquqbqz<!
Ofig<gr<gTg<gig! lm<Ml<! hbe<hMk<Kukx<G! weg<G! kjmObKlqz<jz! we<X!
okiquqk<Kg<ogit<gqOxe<!
    [                         ] 
v. weK! dml<hqzqVf<K! 308.5! ! lq/zq! –! g<G! Olz<! vk<kl<! wMg<gh<hmlim<miK!
we<hjk!fie<!nxqf<Kogi{<Mt<Ote</!!-Vh<hqEl<!weK!dmzqz<!WOkEl<!kQb!
hqe<uqjtUgt<!Wx<hm<miz<?!nkx<gie!hiqOsikjegt<!Olx<ogit<ukx<gig!%Mkz<!
vk<kl<! Okjuh<hm<miz<?! nkx<gie! vk<kk<jk! wMk<Kg<ogit<ukx<Gl<?! wg<^ <Ov?!
=sq\q!lx<Xl<!hqx!hiqOsikjegt<!Olx<ogit<ukx<Gl<!yh<Hkz<!ntqg<gqe<Oxe</! 
    [                         ] 
vi. Olx<%xqb! Nb<uqz<! hr<Ogx<g! fie<! yh<Hkz<! ntqg<gqe<Oxe</! OlZl<! -f<k!
Nb<uieK! Nvib<s<sq! giv{k<kqx<gig! lm<Ml<! ! Olx<ogit<th<hMgqxK! we<hKl<!
weg<Gk<!okiqBl</ 
    [                         ] 
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!
!
yh<Hkz<< << << <!
!
Olx<%xqb!Nb<U!Gxqk<k!kguz<gjt!fie<!hck<Kt<Ote<!/ we<eqml<!okiquqg<gh<hm<mK/!!-f<k!Nb<uqz<!hr<Ogx<g!
weK!Sb!uqVh<hk<kqe<!OhiqOzOb!fie<!yh<Hkz<!ntqg<gqe<Oxe</!!-f<k!Nb<uqz<!hr<Ogx<hkiz<!weg<G!hbOeKl<!
-z<jz! we<hjk! fie<! nxqf<Kogi{<Mt<Ote</! ! -f<k! Nb<uqe<! ohiKuie! Ofig<gl<?! sik<kqbLt<t! kQb! hqe<!
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